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Abstract 
The Continuum of Premenstrual Symptom Exacerbation in Women With and  
Without Psychiatric Comorbidities: A Nurses' Health Study 
Laura Groblewski Leahy 
 
 
Background: 
It is widely known that menstrual cycle fluctuations can significantly affect a woman's 
mood, behavior and quality of life over the course of her reproductive years, largely due to 
reproductive hormonal variations during the course of the menstrual cycle. In fact, women 
are twice as likely as men to experience a mood disorder. Approximately 85% percent of 
women experience some form of premenstrual symptom exacerbation (PME) and the 
majority experience symptoms, which are severe enough to interfere with their daily 
activities. Little is known, however, about the differences in symptom severity, stress, 
quality of life, healthy lifestyle and wellness self-perception among women who experience 
PME with and without psychiatric comorbidities. In addition, little is known about how 
psychiatric comorbidities affect severity of PME, stress, quality of life, healthy lifestyle and 
wellness self-perception. 
Methods: 
This study was conducted using a comparative descriptive design to compare premenstrual 
symptoms, stress, quality of life, healthy lifestyle and wellness self-perception among 
women experiencing PME and psychiatric comorbidities to women who experience PME 
without psychiatric comorbidities. Women with PME were recruited from various nursing 
organizations using secure online surveys. After collection of socio-demographic 
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information, premenstrual symptom severity was measured with the Premenstrual 
Symptoms Screening Tool (PSST), stress with the Perceived Stress Scale (PSS), quality of 
life with the Quality of Life Scale (QOLS) and healthy lifestyle and wellness self-perception 
were assessed using the Healthy Lifestyle Questionnaire (HLQ) & Wellness Self-Perception 
Scale (WSPS). 
Data Analysis: 
The data was cleaned, coded and assessed for outliers and shape of distribution prior to data 
analysis. Analysis included descriptive statistics to describe key characteristics of the 
sample, and inferential statistics to test the hypotheses. 
Results: 
After controlling for diet, exercise, sleep and caffeine intake, psychiatric comorbidities 
predicted greater PME symptom severity (β=0.22; T=2.45; P=0.02), higher perceived stress 
(β=0.25; T=2.61; P=0.01), and lower levels of wellness self-perception (β= -0.30; T= -3.14; 
P=0.00). Psychiatric comorbidities did not predict quality of life  (β= -0.13; T= -1.28; 
P=0.20) or healthy lifestyle (β= -0.13; T= -1.43; P=0.16). 
Significance: 
These findings may inform novel pharmacologic and non-pharmacologic interventions and 
treatment guidelines to achieve optimal symptom management, reduce stress and improve 
wellness self-perception among women with PME and psychiatric comorbidities.
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Chapter 1: INTRODUCTION 
Historical Overview of Premenstrual Symptom Exacerbation (PME) 
 
 It is widely known that menstrual cycle fluctuations can significantly affect mood 
and behavior and quality of life among women over the course of their reproductive years.  
In fact, women are twice as likely as men to experience a mood disorder (Okanagan, 2005) 
and experience considerably higher levels of disability due to depression, anxiety and 
somatic complaints (WHO, 2013), largely due to reproductive hormonal variations during 
the course of the menstrual cycle. Little is known, however, about the differences in 
premenstrual symptom severity, perceived stress, quality of life, healthy lifestyle and 
wellness self-perception between women who experience PME with and without psychiatric 
comorbidities. In addition, little is known about how psychiatric comorbidity affects the 
severity of PME, perceived stress, quality of life, healthy lifestyle and wellness self-
perception. Therefore, this study compared premenstrual symptom severity, perceived stress, 
quality of life, healthy lifestyle and wellness self-perception among women who experience 
PME with and without psychiatric comorbidities. In addition this study evaluated the effect 
of psychiatric comorbidity on severity of PME, perceived stress, quality of life, healthy 
lifestyle and wellness self-perception. 
  While only three to eight percent of menstruating reproductive age women meet the 
DSM-5 (APA, 2013) criteria for premenstrual dysphoric disorder (PMDD) it is estimated 
that 85% percent of women experience premenstrual symptom exacerbation (PME) 
(Pearlstein & Steiner, 2008). A majority of women, who experience PMDD, have 
symptoms, which are severe enough to interfere with their daily activities (Ginsburg & 
Dinsay, 2000). This statistic is highly significant as the reproductive years can span four 
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decades or more for some women; thus, if premenstrual symptom exacerbations occur over 
a span of seven days per month, the woman's quality of life is reduced by three months per 
year or greater than ten years over her reproductive life cycle. Yet, little is known about how 
psychiatric comorbidity affects the severity of PME. Some studies offer correlations 
between the comorbidity of PME and psychiatric disorders; yet, no studies could be located 
that addressed the difference in premenstrual symptom severity, perceived stress, quality of 
life, healthy lifestyle and wellness self-perception between women who experience PME 
with and without psychiatric comorbidities. In addition few studies could be located that 
addressed how psychiatric comorbidity affects the severity of PME, perceived stress, quality 
of life, healthy lifestyle and wellness self-perception. 
Premenstrual Symptom Exacerbation and the Menstrual Cycle   
 Women have unique pharmacokinetics, which differ greatly from that of men. The 
female reproductive hormones fluctuate across the menstrual cycle and modulate affective 
symptoms through their action in the central nervous system (Rubinow & Schmidt, 2006).  
 
FIGURE 1.1: Phases of the Menstrual Cycle & PME (adapted from napmdd.org, 2015) 
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As a result of these fluctuations in progesterone and estrogen, mood disturbances are 
induced in those women who experience PME, but not in those who do not experience PME 
(Schmidt, Nieman, Danaccau, Adams & Rubinow, 1998). Figure 1.1 illustrates the hormonal 
fluctuations across the menstrual cycle and the typical onset and duration of PME. Despite 
these research findings, the available studies exploring the distinct relationship between 
psychiatric disorders and hormonal exacerbations are limited.  
  Such hormonally induced mood exacerbations are more commonly referred to as 
premenstrual syndrome (PMS) or premenstrual dysphoric disorder (PMDD). The American 
College of Obstetricians and Gynecologists (ACOG) diagnostic criteria for the diagnosis of 
PMS can be found in Figure 1.2.  
 
FIGURE 1.2: ACOG Diagnostic Criteria for Premenstrual Syndrome (ACOG, 2000). 
Patient reports at least one of each of the following affective and somatic symptoms during        
the 5 days before menses. Symptoms must appear in three consecutive menstrual cycles: 
Affective: Depression, angry outbursts, irritability, anxiety, confusion, social withdrawal 
Somatic: Breast tenderness, abdominal bloating, headache, swelling of extremities 
Symptoms must also meet the following criteria: 
• Be relieved within 4 days of the onset of menses, without recurrence until at                     
least cycle day 13 
• Be present in the absence of any pharmacologic therapy, hormone ingestion,                                  
or drug or alcohol use 
• Be causing identifiable dysfunction in social or economic performance 
• Occur reproducibly during two cycles of prospective recording 
 
According to the DSM-5, PMDD (refer to Figure 1.3) is characterized as a disorder 
occurring during the week prior to a woman's menstrual cycle and includes the following mood 
related symptoms: anger, irritability, depressed mood, anxiety, emotional lability, “edginess,” 
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and moodiness. Other symptoms include: fatigue, sleep disruption, changes in appetite, 
decreased interests, poor concentration, bloating, breast tenderness and a sense of being 
overwhelmed. The diagnosis can be confirmed by prospective daily ratings during two or more 
consecutive, symptomatic menstrual cycles in which the symptoms occur during the luteal phase 
of the cycle and interfere with work, school and the woman’s usual activities (APA, 2013).   
In the United States, while PMS and PMDD are often referred to interchangeably, they 
are actually varying states on the continuum of Premenstrual Symptom Exacerbation (PME).  
For the remainder of this dissertation, the term Premenstrual Symptom Exacerbation (PME) will 
be utilized to encompass the continuum of hormonally exacerbated premenstrual disorders 
including PMS and PMDD.
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FIGURE 1.3: DSM 5 Diagnostic Criteria for Premenstrual Dysphoric Disorder (APA, 2013) 
A. In most menstrual cycles during the past year, five (or more) of the following symptoms were  
present for most of the time during the last week of the luteal phase, began to remit within a few  
days after the onset of the follicular phase, and were absent in the week post-menses, with at  
least one of the symptoms being 1, 2, 3, or 4: 
 
  1. Markedly depressed mood, feelings of hopelessness, or self-deprecating thoughts 
  2. Marked anxiety, tension, feelings of being “keyed up” or “on the edge” 
  3. Marked affective lability (e.g., feeling suddenly sad or tearful or increased                         
sensitivity to rejection) 
  4. Persistent and marked anger or irritability or increased interpersonal conflicts 
  5. Decreased interest in usual activities (e.g., work, school, friends, hobbies) 
  6. Subjective sense of difficulty in concentrating 
   
  7. Lethargy, easy fatigability, or marked lack of energy 
  8. Marked change in appetite, overeating, or specific food cravings 
  9. Hypersomnia or insomnia 
 10. A subjective sense of being overwhelmed or out of control 
 11. Other physical symptoms, such as breast tenderness or swelling, headaches, joint                                   
or muscle pain, a sensation of “bloating,” weight gain 
 B. The symptoms are associated with clinically significant distress or markedly interferes                       
with work or school or with usual social activities and relationships with others (e.g.,         
avoidance of social activities, decreased productivity and efficiency at work or school) 
 
C. The disturbance is not merely an exacerbation of the symptoms of another disorder, such      
     as Major Depressive Disorder, Panic Disorder, Dysthymic Disorder, or a Personality Disorder                   
     (although, it may be superimposed on any of these disorders). 
D. Criteria A, B, and C must be confirmed by prospective daily ratings during at least two       
consecutive somatic cycles. (A provisional diagnosis may be made prior to this confirmation) 
 E. The symptoms are not attributable to the physiological effects of a substance (e.g., a drug 
of abuse, a medication, other treatment) or another medical condition (e.g., hyperthyroidism). 
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 Epidemiology and Comorbidity of Premenstrual Symptom Exacerbation  
   
 PME may occur any time after a woman reaches menarche, though the typical age of 
symptom onset occurs when the woman is in her teens to late twenties. Despite this early onset, 
treatment may not be sought until the woman enters her thirties (MGH-Center for Women’s 
Mental Health, 2013). Over the woman's lifetime, PME symptoms tend to occur over the 
majority of menstrual cycles and worsen with age until menopause (MGH, 2013).   
 Approximately 85% of premenopausal women experience mild PME and 19% experience 
severe PME, commonly known as premenstrual dysphoric disorder. Retrospectively, 25% to 
68% (Payne, Roy & Murphy-Eberenz et al, 2007) and prospectively, 55% to 65% (Angst, 
Sellaro, Merikangas & Endicott, 2001) of women diagnosed with major depressive disorder or 
bipolar disorder report experiencing comorbid PME. To a larger degree, approximately 60% of 
women, who charted their symptoms prospectively and were diagnosed with Major Depressive 
Disorder or Bipolar Disorder, reported premenstrual exacerbation of their comorbid mood 
symptoms (Dias et al, 2011). Similarly, Richards and colleagues (2006) found that women 
diagnosed with depression experienced higher rates of premenstrual dysphoria. In a study of over 
3,500 women, Forrester-Knauss and colleagues (2011) reported a 0.359 correlation between the 
symptoms of Major Depressive Disorder and PME. Hsiao, Hsiao & Liu (2004) suggest a high 
correlation between the various psychiatric disorders (Generalized Anxiety Disorder 52%, 
Depressive Disorder 52%, Panic Disorder 36% and Schizophrenia 20%) and PME. So while we 
know that PME and psychiatric disorders are correlated, we do not know the effect of 
psychiatric comorbidity on the severity of PME, perceived stress, healthy lifestyle, quality of 
life and wellness self-perception 
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Health Determinants & Risk Factors for PME 
 PME includes a highly heritable constellation of symptoms. Studies have indicated that 
daughters have a 70% chance of experiencing PME if their mother experiences/experienced 
PME. Likewise, almost two-thirds of daughters of women without PME are also likely to be 
symptom free (Kantero & Widholm, 1971). Women of reproductive age may inherit or 
experience health determinants (refer to Figure 1.4), which increase their risk for developing 
PME.  This section will explore the various biological factors and stress and lifestyle factors, 
which affect the severity of PME. Since little is known about the specific effect of psychiatric 
comorbidity and PME, this section will also explore what is known about the effect of PME on 
quality of life and wellness self-perception, regardless of psychiatric comorbidity.  
 Biological factors. According to Balaha (2010) biological risk factors for PME include 
an early age a menarche, regular menstrual cycles, a family history of PME, and a history of 
depression and/or anxiety. Polymorphisms in the serotonin transporter gene (SLC6A4) may also 
increase the severity of symptoms of both PME and psychiatric illness (Praschak-Rieder, Willeit, 
Winkler et al, 2002). The short allele (s/s or s/l) genotype has been found to contribute to higher 
levels of depressive and anxiety spectrum symptoms than the long allele (l/l) genotype of the 
serotonin transporter gene (Lesch, Begel, Heils et al, 1996). While there is an association 
between PME, family history (P=0.003) and the short allele genotype of the serotonin 
transporter gene  (P=0.033), further research needs to be conducted to determine the relationship 
of genetic polymorphisms to PME (Praschak-Rieder et al, 2002).  
 Various illnesses affecting the pelvic viscera, such as: urinary tract infections, pelvic 
inflammatory disease, endometriosis and interstitial cystitis, may also contribute to a woman's 
susceptibility toward PME (Smith, 1993). Additionally, dysmenorrhea (Potter, 2009) and an 
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imbalance in prostaglandins (Dawood, 1990) may also leave a woman more vulnerable to the 
symptoms of PME. According to Angst and colleagues (2001), approximately 60% of women 
diagnosed with psychiatric disorders (major depressive disorder, anxiety disorders or bipolar 
disorder) prospectively report premenstrual exacerbation of their psychiatric symptoms.  
FIGURE 1.4: Health Determinants of the Severity & Impact of PME 
 
 
  
 Stress. There are many life stressors, which have been identified as contributing to a 
woman's risk of developing PME. Ussher (2004) inferred that negative cognitive schema linked 
to life stressors increase the risk of developing PME. Lustyk and colleagues (2004) found that 
women with PME experienced higher levels of stress, which in turn augmented PME 
symptomatology. They also noted that PME affected levels of occupational stress and relational 
stress, including: family stress and social stress. Thus, stress can be viewed as both a risk factor 
for and an outcome of PME. While these studies reflect the effect of stress on the severity of 
PME, little is known about the effect of psychiatric comorbidities on perceived stress. 
Severity 
of
PME
Biological Factors
• Psychiatric Illness
• Heredity (genetics)
• Serotonin
• Hormones
Stress
• Occupational Stress
• Relational Stress
Lifestyle Factors
• Diet & Nutrition
• Exercise
• Sleep
Quality of Life 
& 
Wellness 
Self-Perception
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 Lifestyle Factors. Various lifestyle factors also place women at risk for the development 
of PME and influence symptom severity. A diet high in processed foods, caffeine, sugar, dairy 
and meats, coupled with a sedentary lifestyle, contribute significantly to the risk of a woman 
experiencing hormonally induced symptom exacerbations (faqs.org, 2011). A lifestyle without 
exercise and with poor dietary intake may exacerbate the severity of premenstrual symptoms 
during a woman's reproductive years. Additionally, behavioral changes, dietary adjustment and 
exercise may reduce the severity of PME by reducing stress and improving quality of life (Lustyk 
and Gerrish, 2010). These studies, however, do not reflect the effect of psychiatric comorbidities 
on PME symptom severity in relation to the aforementioned factors contributing to a healthy 
lifestyle. 
Effect of PME on Quality of Life and Wellness Self-Perception 
 
 Women experiencing PME report symptoms which parallel those of psychiatric illness 
and experience a negative mental health related quality of life burden which exceeds that of both 
the general population and that of women with chronic back pain (Yang et al., 2008). El-Masry 
and Abdelfatah (2012) found that women with PME experienced a lower quality of life than the 
healthy female population.  Lustyk and colleagues (2004) also found that PME is associated with 
poor quality of life in women. While these studies reflect the general female population, the 
effect of PME among women with psychiatric comorbidities on quality of life and wellness self-
perception remains unstudied.  
Statement of the Research Study  
 While there are several research studies that have increased the understanding of the 
effects of biological factors, stress and healthy lifestyle on the severity of PME symptoms 
and the effects of PME on quality of life and wellness self-perception among women 
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without comorbid psychiatric disorders, little is known about the effect of psychiatric 
comorbidities on these factors as they relate to comorbid PME in reproductive age women. 
Purpose of the Research Study     
 The purpose of this comparative descriptive study was to compare the premenstrual 
symptom severity, perceived stress, healthy lifestyle, quality of life, and wellness-self-
perception among women experiencing PME with and without psychiatric comorbidities. 
This study also determined the effect of psychiatric comorbidity in women with PME on 
premenstrual symptom severity, perceived stress, healthy lifestyle, quality of life and 
wellness self-perception. This study provides the critical foundation from which novel 
treatment interventions and symptom management guidelines can be developed for women 
who experience PME and comorbid psychiatric disorders. 
Specific AIMS of the Research Study 
The specific aims of this study were to: 
 
 1. Compare premenstrual symptom severity between women with PME with and 
without psychiatric comorbidities. 
      2. Compare perceived stress between women with PME with and without psychiatric  
 
comorbidities.  
 
 3. Compare healthy lifestyle between women with PME with and without psychiatric  
 
comorbidities. 
 
 4. Compare quality of life between women with PME with and without psychiatric  
 
comorbidities.  
 
 5. Compare wellness self-perception between women with PME with and without  
 
psychiatric comorbidities. 
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Research Hypotheses 
 
The research hypotheses for this study were as follows: 
  
 1. Women with PME and psychiatric comorbidities would experience more severe  
 
premenstrual symptom severity than women with PME without psychiatric comorbidities. 
 
 2. Women with PME and psychiatric comorbidities would experience greater 
perceived stress than women with PME without psychiatric comorbidities. 
 3.  Women with PME and psychiatric comorbidities would experience a less healthy  
 
lifestyle compared to women with PME without psychiatric comorbidities.  
 
 4. Women with PME and psychiatric comorbidities would experience lower 
 
quality of life than women with PME without psychiatric comorbidities. 
 
 5. Women with PME and psychiatric comorbidities would experience lower levels of  
 
wellness self-perception compared to women with PME without psychiatric comorbidities. 
 
Operational Definitions 
Premenstrual Exacerbation is defined as the premenstrual worsening of a pre-
existing psychiatric disorder (Hsiao,  Hsiao & Liu, 2004). Premenstrual exacerbation 
is further defined in this study as the magnification of psychic/somatic anxiety for 
patients with generalized anxiety disorder, aggravation of any DSM-IV [to DSM-5] 
based symptom of a depressive disorder for patients with depression, increased 
incidence of un-cued full-panic attack for patients with panic disorder, and 
aggravated positive or disorganized symptoms patients with schizophrenia (Hsiao, 
Liu, Chen & Hsieh, 2002). As Premenstrual Syndrome and Premenstrual Dysphoric 
Disorder (see definitions below) are disorders on the continuum of PME, only the 
term PME will be utilized throughout this research study to indicate this spectrum of 
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hormonally exacerbated symptoms. Symptom severity was measured with the 
Premenstrual Symptoms Screening Tool (PSST) (Steiner, Macdougall & Brown, 
2003).  
 Premenstrual Syndrome is defined as a complex health concern involving a 
 variety of physical, mental and behavioral symptoms occurring during the 
 two weeks prior to a woman's period and resolving after the first day or two 
 of menstrual flow (Stöppler, 2014). 
  
 Premenstrual Dysphoric Disorder is defined as serious premenstrual 
 distress associated with deterioration in functioning and characterized by 
 depressed or labile mood, anxiety, irritability, anger and other symptoms 
 occurring during the two weeks prior to the onset of menses and subsiding 
 shortly thereafter (Htay, 2014). 
  
Psychiatric Disorders are defined as any pattern of psychological or behavioral 
symptoms that causes an individual significant distress, impairs their ability to 
function in life, and/or significantly increases their risk of death, pain, disability, or 
loss of freedom. In addition, to be considered a psychiatric disorder, the symptoms 
must be more than an expected response to a particular event (e.g., normal grief after 
the loss of a loved one) (Salters-Pedneault, 2014). Depressive, anxiety and bipolar 
disorders are all part of the various psychiatric comorbidities referred to throughout 
this dissertation. 
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 Depressive Disorders are defined as a syndrome or group of symptoms that 
 reflects a sad and/or irritable mood exceeding normal sadness or grief. The 
 sadness of depression is characterized by a greater intensity and duration and 
 by more severe symptoms and functional disabilities than is normal (Dryden-
 Edwards, 2014). Disturbance in sleep, appetite, and mental processes are 
 common accompaniments.  
 
 Anxiety Disorders are defined as chronic conditions characterized by 
 excessive, persistent and unrealistic worry and apprehension, often 
 accompanied by physical symptoms such as sweating, palpitations, 
 nightmares and feelings of dread. Examples include: Generalized Anxiety 
 Disorder, Obsessive Compulsive Disorder, Panic Disorder, Social Anxiety 
 Disorder and Post Traumatic Stress Disorder (APA, 2013). 
   
  Bipolar Disorder is defined as: A disorder of the brain that causes unusual 
  shifts in mood, energy, activity levels, and the ability to carry out daily tasks. 
  Bipolar I Disorder, the most common diagnosis, is defined by manic or  
  mixed episodes that last at least seven days, or by manic symptoms that are 
  so severe that the person needs immediate hospital care. Usually, depressive 
  episodes occur as well, typically lasting at least 2 weeks (APA, 2013). 
  
 Stress is defined as feelings or thoughts that an individual has about how much 
 stress they are under at a given point in time or over a given time period. Perceived 
 stress incorporates feelings about the uncontrollability and unpredictability of one’s 
 life, how often one has to deal with irritating hassles, how much change is occurring 
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 in one’s life, and confidence in one’s ability to deal with problems or difficulties 
 (Phillips, 2013). Stress was measured utilizing the Perceived Stress Scale (PSS) 
 (Cohen, 1983) 
 
Healthy Lifestyle is defined as an active process of becoming aware of and making 
choices toward a healthy and fulfilling life. According to WHO (1948), health is 
defined as "a state of complete physical, mental and social well-being and not merely 
the absence of disease or infirmity." Healthy Lifestyle was measured utilizing the 
Healthy Lifestyle Questionnaire (HLQ) (Corbin & Welk, 2008). 
 
Quality of Life is defined as the patient's ability to enjoy normal life activities. 
Quality of life is an important consideration in medical care. Some medical 
treatments can seriously impair quality of life without providing appreciable benefit,  
            whereas others greatly enhance quality of life (Shiel, Marks, Stoppler &    
            Davis, 2012). Quality of Life was measured utilized the Quality of Life   
 Scale (QOLS) (Flanagan, 1978).  
 
Wellness Self-Perception is defined as “the individual's assessment of his or her 
physical, emotional, social, spiritual,  environmental and intellectual status. It is 
possible to be dying and still feel well if death is accepted and peace is prevalent 
(Chambers Clark & Paraska, 2012, p. 6)." Wellness Self-Perception was measured 
utilizing the Wellness Self-Perception Scale (WSPS) (Corbin & Welk, 2008).
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Significance to Clinical Nursing Practice 
 Nurse Practitioners in various healthcare settings, such as psychiatry, primary care, 
and women’s health often interface with women who experience PME and comorbid 
psychiatric disorders. Not only are nurse practitioners called upon to treat the psychiatric 
symptoms, but also to manage the overlay of symptom dysregulation some women 
experience due to hormonal oscillation across their menstrual cycles. According to the 
American College of Obstetricians and Gynecologists (ACOG, 2003), roughly 85% of 
women, who experience at least one physical and one emotional symptom consecutively 
across three menstrual cycles, have symptoms severe enough to interfere with their daily 
activities. Additionally, Yang and colleagues (2008) found that women with PME 
experienced negative mental health related quality of life burden which exceeded that of 
both the general population and that of women with chronic back pain and rivaled the 
burden of women with type II diabetes, osteoporosis, rheumatoid arthritis and hypertension. 
Nurse practitioners, who often use a holistic approach to healthcare, will be on the frontlines 
of treating women who experience premenstrual symptom exacerbation and co-occurring 
psychiatric comorbidities.  
 The potential effect of hormonally induced mood exacerbations in women with 
comorbid psychiatric disorders has a tremendous significance for the nurse practitioners 
entrusted to provide their care, especially given the lack of literature available on this topic.  
There is certainly a need to further identify and describe this population and how psychiatric 
comorbidities affect the premenstrual symptom severity, perceived stress, healthy lifestyle, 
quality of life and wellness self-perception compared to women who experience PME 
without psychiatric comorbidities. This study provides the foundation by describing these 
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specific phenomena, which will serve to inform novel interventions and treatment guidelines 
for these women who experience PME and psychiatric comorbidities during their 
reproductive lifecycles.  
Summary 
 Nurse Practitioners in most settings will at one time or another work with a woman 
who experiences PME and co-occurring psychiatric comorbidities. The findings of this 
research study may serve to inform interventions and treatment guidelines to achieve 
optimal symptom management, reduce perceived stress, improve quality of life, enhance 
healthy lifestyle and improve wellness self-perception among women with comorbid PME 
and psychiatric disorders.  
In order to fully understand this phenomenon one must understand the state of the 
science on the following: a) the effect of biological factors on PME, b) the effect of stress on 
PME, c) the effect of healthy lifestyle factors on PME, d) the effect of PME on the woman's 
overall quality of life, and e) the effect of PME on a woman's self-perception of wellness. In 
addition, it is important to understand what is known about psychiatric comorbidity and its 
relationship to the premenstrual symptom severity, perceived stress, healthy lifestyle, quality 
of life and self-perception of wellness. Evidence of these key variables is further explored 
and synthesized in Chapter 2.
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Chapter 2: LITERATURE REVIEW  
 This integrative review explores the relevant studies regarding premenstrual symptom 
exacerbation (PME), and relevant studies on biological factors, stress and healthy lifestyle, quality of 
life, and wellness self-perception among women experiencing PME with and without psychiatric 
disorders.  
Literature Search Criteria 
 
 Drexel University's Health Sciences Libraries and The University of Pennsylvania's Biomedical 
Library's databases were accessed to obtain relevant studies for inclusion. The keywords: 'psychiatric 
symptoms,' 'premenstrual exacerbation,' 'PMS,' 'PMDD,' 'reproductive age,’ 'psychiatric disorders,' 
'stress,' 'quality of life,' 'healthy lifestyle,' and 'wellness self-perception' were entered into the bio-
medical databases (CINAHL, PubMed, and OVID) and an additional search was conducted through the 
same databases for journal articles related to the effect of hormonally induced symptom exacerbation 
and comorbid psychiatric illness in women. To remain current, the initial search was limited to articles 
published from the year 2007 to present; however, given the paucity of relevant literature, the dates were 
expanded to include articles from 2000 to present. Only peer-reviewed articles were included and the 
language was restricted to English.  
 The database searches produced 90 articles in total; however, a majority of the articles  
were excluded because they did not pertain to women of reproductive age, premenstrual symptom 
exacerbation (PME), premenstrual syndrome, premenstrual dysphoric disorder, psychiatric symptoms or 
psychiatric disorders. A total of eleven pertinent studies regarding reproductive age women with PME 
and psychiatric comorbidities were identified through the database searches. Table 2.1 offers an 
overview of the included studies related to PME among women with psychiatric comorbidities. An 
additional nine studies were identified which explored the experience of PME among women without 
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psychiatric comorbidities with regard to biological factors, the effect of stress and healthy lifestyle on 
the severity of PME and the effect of PME on quality of life and wellness self-perception. 
 It is significant to note that the literature search yielded neither nurse-authored articles nor 
publications in nursing journals. Also of significance is the dearth of literature exploring the effect of 
psychiatric comorbidities on severity of PME among reproductive-age women. No articles were found 
defining the effect of comorbid psychiatric disorders on premenstrual symptom severity, perceived 
stress, healthy lifestyle, quality of life and wellness self-perception. 
What is Known About PME Among Women Without Psychiatric Disorders? 
Biological factors. According to Balaha (2010), biological risk factors for PME include early 
age menarche, regular menstrual cycles, a family history of PME, and a history of depression and/or 
anxiety. This comparative cross-sectional study conducted at King Faisal University in Saudi Arabia 
compared 89 female students with PME to 161 female students without PME. Logistic regression 
analysis revealed that women with lower age at menarche (χ2= 10.69; P=0.001), regularity of menses 
(χ2==23.26; P=0.000) and family history of PME (χ2=19.68; P=0.000) were more likely to experience 
PME. Additionally, the level of impairment due to depression (74.1% vs 17.5%; P=0.003) and stress 
(82.9% vs 25%; P=0.004) was statistically higher in the group with more severe PME.  
Family history and polymorphism in the serotonin transporter gene (5-HTTLPR) may increase 
the severity of symptoms of both disorders (Praschak-Rieder, Willeit, Winkler et al, 2002). The short 
allele (s/s or s/l) genotype has been found to contribute to higher levels of depressive and anxiety 
spectrum symptoms and disorders than the long allele (l/l) genotype of the serotonin transporter gene 
(Lesch, Begel, Heils et al, 1996). In an outpatient German mental health clinic, this prospective 
comparative cross sectional study comparing 48 females with seasonal affective disorder (SAD) and 
comorbid PME to 39 females with SAD without PME. In this study, Praschak-Rieder and colleagues 
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(2002) found that women were more likely to experience PME with a positive family history of PME 
(OR=3.601; P = 0.003) and a serotonin transporter s/l allele genotype (OR=2.676; P = 0.033) in 
women with psychiatric comorbidity. This prospective study was conducted at an outpatient clinic in 
Vienna, Austria. Various illnesses impacting the pelvic viscera, such as: urinary tract infections, 
pelvic inflammatory disease, endometriosis and interstitial cystitis, may also contribute to a woman's 
susceptibility toward PME (Smith, 1993). Additionally, dysmenorrhea (Potter, 2009) and an 
imbalance in prostaglandins (Dawood, 1990) may also leave a woman more vulnerable to the 
symptoms of PME. 
Angst and colleagues (2001) conducted an eight-year prospective longitudinal study of 299 
Swiss women to examine the prevalence, clinical significance and comorbidity of PME symptoms. 
Irritability and depression were the symptoms most strongly associated with PME (44.6% and 29.1%, 
respectively). Angst and colleagues (2001) also found that subjective distress related to PME highly 
correlated with impairment in occupational, relational, social and leisure functioning (r= 0.41-0.53; 
P=0.001). While these biological factors may predispose women to PME, we do not know the effects 
of psychiatric comorbidity on premenstrual symptom severity, perceived stress, healthy lifestyle, 
quality of life or wellness self-perception. 
Stress. There are many life stressors contributing to the severity of PME. In a retrospective 
comparative cross-sectional study of 44 female college students from Seattle Pacific University in 
Washington with high levels of PME compared to 38 female students with low levels of PME, Lustyk 
and colleagues (2004) found that women with higher PME experienced higher levels of stress (t=3.27; 
P = 0.002) and poorer quality of life than those women with lower PME (M=2, SD=1.5 vs M=3, 
SD=0.92, respectively; P = 0.01). They also noted that PME affected occupational functioning and 
quality of relationships, including: family, occupational and social relationships. Thus, stress can be 
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viewed as both a risk factor for and an outcome of PME.  While these studies reflect the bidirectional 
relationship of stress to PME, little is known about the effect of psychiatric comorbidities on PME 
symptom severity and perceived stress. 
 Lifestyle factors Various lifestyle factors also place women at risk for the development of 
PME and influence symptom severity. A diet high in processed foods, caffeine, sugar, dairy and 
meats, coupled with a sedentary lifestyle, contribute significantly to the risk of experiencing 
hormonally induced symptom exacerbations (faqs.org, 2011). A lifestyle without exercise and with 
poor dietary intake may exacerbate the severity of premenstrual symptoms during a woman's 
reproductive years. Additionally, behavioral changes, dietary adjustment and exercise may reduce the 
severity of PME by reducing stress and improving quality of life (Lustyk and Gerrish, 2010).  
 In one such comparative cross sectional case control study of 160 Iranian nurses with PME 
compared to 160 Iranian nurses without PME, Negin, Fereydoun, Fariba and colleagues (2015) found 
that women who consumed a Western diet were more likely to experience higher severity of PME 
than those who consumed a healthy or traditional Middle Eastern diet (OR 4.39; P<0.05). In a quasi-
experimental randomized controlled study of forty non-athletic students with PME at Khorasgan 
Azad University in Iran, Samadi, Taghian and Valiani (2013) found that the women who exercised 
experienced a significant reduction in severity of PME (physical and psychological symptoms) 
compared to controls who did not exercise (60% physical, 65% psychological and 52% overall, 
respectively; P≤0.001). These studies, however, do not reflect the effect of psychiatric comorbidities 
on PME in relation to the aforementioned lifestyle factors, quality of life or wellness self-perception. 
Effect of PME on Quality of Life and Wellness Self-Perception 
 Women experiencing PME report symptoms which parallel those of psychiatric illness and 
experience a negative mental health related quality of life burden which exceeds that of both the 
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general population and that of women with chronic back pain (Yang et al., 2008). In a comparative 
case-control study of 68 reproductive age women, conducted in Egypt, El-Masry and Abdelfatah 
(2012) found that thirty-four women with PME experienced a lower quality of life than the thirty-four 
healthy females without PME related to the psychological domain, including emotional and health 
adjustment and the social domain, and family and social adjustment (t=9.5 vs t=4.46; P< 0.001). A 
similar comparative case-control study by Pinar, Colak and Oksuz (2011) of 316 female students at 
Baskent University in Turkey found that PME significantly reduced the quality of life in the physical 
and environmental domains for these women (F=21.29 and F=87.947, respectively; P <0.00).  
Pinar and colleagues' (2011) also found that consuming more than 2 cups of coffee daily, 
smoking cigarettes, and consuming alcohol (t=10.529; P=0.001; t=18.961; P=0.000 and t=3.979; 
P=0.044; respectively), were risks factors for and had a significant negative effect on the healthy 
lifestyle of women with PME. Hourani, Yuan and Bray (2004) conducted a comparative case control 
study of 6,026 active duty females representing all branches of the military via a series of three 
questionnaire mailings to identify an association between job stress and premenstrual symptoms. 
Logistic regression analysis found that military women with PME were significantly more likely to 
experience an overall lower self-perception of health and wellness than healthy peers without PME 
(OR=2.15; P<0.05). Compared to their peers without PME, Hourani and colleagues' study also found 
that military women with PME were more likely to experience greater difficulty in losing weight, 
drink more heavily, and experience higher levels of overall job stress (OR=1.79; P<0.001; OR=1.62; 
P<0.005 and OR=2.76; P<0.001, respectively) when controlling for all other variables. While these 
studies reflect findings in the general female population, the effect of psychiatric comorbidities on the 
premenstrual symptom severity, quality of life and wellness self-perception in women with 
psychiatric comorbidities remains unstudied. 
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What is Known About PME Among Women with Psychiatric Disorders?  
 PME is fairly well documented among women without comorbid psychiatric disorders.  
What is not well documented or published, however, is literature describing and comparing the 
physical and emotional symptoms of PME, perceived stress, quality of life, healthy lifestyle and 
wellness self-perception among women with PME and comorbid psychiatric disorders such as 
depression, anxiety or bipolar disorder to women with PME without psychiatric disorders. This 
section reviews the primary studies related to these comorbid conditions over the last decade. 
Table 2.1 at the end of this section offers an overview of the literature related to PME and 
psychiatric comorbidities. 
 PME and depressive disorders. Exacerbation of depressive symptoms was found to be a 
common finding related to the luteal phase of the menstrual cycle (Benavente, Martin et al., 2010; 
DeRonchi et al., 2005; Forrester-Knauss et al, 2011, Richards et al., 2006; Dias et al., 2011; and 
Karadag et al., 2012). In a prospective controlled trial comparing 43 women with late luteal phase 
dysphoric disorder (LLPD) compared to 85 women without LLPD from an outpatient OB/GYN 
service in Ravenna, Italy, findings suggest that women with Major Depressive Disorder (MDD) 
were more likely to experience LLPD than women without MDD (OR =1.9; P < 0.001) and that 
LLPD may represent a variant of depressive disorders (DeRonchi et al, 2005). In a cross-sectional 
case control study, Forrester-Knauss and colleagues (2011) found that 35.9 percent of women with 
PME also suffered from comorbid major depression (MDD) (X2=11.58; P<0.01). Women with medium 
and high psychological distress and PME were more likely (OR= 1.68 and 3.32 respectively; P<0.001) 
to experience MDD. Their evaluation of over 3,500 reproductive age Swiss women, postulated that 
PME and MDD are separate psychiatric disorders that can co-exist.  
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In a comparative case control study conducted by Benavente and colleagues (2010) in Vigo, 
Spain, 48 women with PME and 26 women without PME were recruited from mental health units. This 
study found that women with PME experienced higher rates of seasonal depression than those without 
PME (49.2% vs. 22.2%; P=0.008). Finally, in a comparative cross-sectional case control study of 70 
depressed women and 35 non-depressed women with menstrual cycle irregularities, Richards and 
colleagues (2006) found that depressed women experienced higher rates of premenstrual dysphoria. 
This study, conducted at the Menopause Clinic of the National Institute of Mental Health, found that a 
significantly higher proportion of depressed women suffered from PMDD compared to non-depressed 
women  (21% vs 3%; P=0.04).   
 While the aforementioned studies noted correlations between depression and PME, 
they did not compare the effect of depressive comorbidity on PME severity in depressed 
women to PME severity in women without depression. There is little research to date that 
thoroughly describes the symptoms, both physical and emotional, of PME in women with 
depression. Additionally, the current studies do not explore the effect of PME and 
psychiatric comorbidities on perceived stress, quality of life, healthy lifestyle and wellness 
self-perception. 
 PME and bipolar disorders. In a multiple site comparative cross sectional case-control study of 
almost 300 American women with bipolar disorder and comorbid PME, Dias and colleagues (2011) 
found that comorbid PME leads to more frequent bipolar episodes and more depressive symptoms 
(46.1% vs 32.4%; P=0.04 and 34% vs 18.6%; P<0.01 respectively) compared to women diagnosed with 
bipolar disorder and no PME. This study also found that women with Bipolar disorder and comorbid 
PME also experience greater interference with work/school than women with bipolar disorder without 
PME (78.1% vs 23.7%, respectively; P<0.001).  
    
 
    
   
 
 
24
Karadag and colleagues (2012) conducted a comparative cross sectional case control study in 
three mood disorder outpatient clinics in Istanbul, Turkey. This study of 34 women with bipolar disorder 
who were prescribed mood stabilizing psychotropic medications and 35 healthy controls, reported that 
women with treatment responsive bipolar disorder who were prescribed the mood stabilizers Lithium or 
Valproate experienced significantly less premenstrual exacerbation of depressive, anxiety and 
attentional symptoms than did healthy controls (M=175.3, SD=60.2 vs M=218.2, SD=69.9, respectively; 
U = 385.5; P<0.05). These findings are also significant in that they suggest that mood-stabilizing agents, 
such as Lithium and Valproate, may have a prophylactic effect on premenstrual exacerbation of 
psychiatric symptoms in addition to treating the comorbid psychiatric illness. 
 In a Korean medical center comparative cross sectional case-control study, Choi and colleagues 
(2010) found that women with bipolar disorder experienced more seasonal mood changes and 
premenstrual psychiatric symptoms regardless of their bipolar cycling. The study compared 61 women 
with Bipolar I or II disorder to 122 healthy controls. Women with bipolar disorder experienced 
significantly higher rates of PME compared to healthy controls (74.9% vs 19.7%; P=0.001).  These 
findings again reinforce the notion that women with psychiatric disorders experience PME as a 
condition distinctly separate from bipolar disorder. Additionally, the study also found that women with 
bipolar disorder experience higher rates of seasonal affective disorder than healthy controls (49% vs 
3.3%; P<0.000). 
 Fornaro and Perugi (2010) conducted a study of 92 women diagnosed with Bipolar disorder in 
Genoa Italy. This comparative case-control study compared 25 women with comorbid PMDD to 67 
women without PMDD. Rates of comorbid Bipolar II disorder and cyclothymia were higher in women 
who experienced PMDD than in those who did not experience PMDD (88% vs 60%; P<0.000 and 72% 
vs 36%, respectively; P=0.002). Additionally, postpartum depression was reported more frequently by 
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women with PMDD than women without PMDD (36% vs 14.9%; P=0.026). Finally Obsessive 
Compulsive Disorder and Body Dysmorphic Disorder were represented to a much greater extent in 
women who experienced PMDD than women who did not experience PMDD (24% vs 7.5%; P=0.03 
and 24% vs 6%; P=0.01, respectively).  
 While these studies indicate the potential comorbid existence of PME and bipolar disorder, there 
is little data available to fully understand the phenomena of co-occurring psychiatric mood disorders and 
their effect on PME symptom severity. There are no studies that explore the effect of psychiatric 
comorbidities on perceived stress, quality of life, healthy lifestyle, and wellness self-perception among 
women with bipolar disorder and PME. 
  PME, anxiety and other psychiatric disorders. In a comparative cross sectional study 
of 91 female college students from American University in Washington, DC, Portella, Haaga, and 
Rohan (2006) found a significant correlation between the symptoms of seasonal affective disorder 
(SAD) and PME (r = 0.45; P<0.001). While this study explored the correlation between PME and 
SAD, it did not address the effect of SAD on premenstrual symptom severity, perceived stress, 
healthy lifestyle, quality of life and wellness self-perception.   
In addition to exacerbation of depressive symptoms during the luteal phase, women have 
also experienced increased symptoms of anxiety and hostility. In their prospective comparative 
controlled study of 67 women with PMDD and 75 healthy controls at Kaosiung Medical 
University in Taiwan, Ko, Long, Chen and colleagues (2013) reported that depression, anxiety 
and hostility (t=6.036 vs t=0.836; t=6.314 vs t=1.170 and t=5.897 vs t=0.405, respectively; 
P<0.001) symptoms were exacerbated in women diagnosed with PME but not in those without 
PME. Correlational analysis of these variables also indicated that a higher proportion of women 
with irritability during the premenstrual phase experienced more functional impairments, 
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impairments in work efficiency, and impairments in coworker relationships (0.34 vs 0.23; 0.32 vs 
0.09 and 0.35 vs 0.19; respectively; P<0.01) than women without PMDD. Finally, a Taiwanese 
comparative cross sectional study conducted by Hsiao, Hsiao and Liu (2004) compared 200 
women with regular menses and various psychiatric disorders. Their study found that the 
following psychiatric disorders: generalized anxiety disorder, depressive disorders, panic disorder 
and schizophrenia (52%, 52%, 36% and 20%, respectively, X2=18.4, df=3; P<0.005), was 
significantly correlated with PME. 
 While the aforementioned studies noted a correlation between psychiatric comorbidities and 
PME, they did not adequately describe the effect of psychiatric comorbidity on premenstrual symptom 
severity or compare premenstrual symptom severity between women with and without psychiatric 
comorbidities. There is a paucity of research that thoroughly describes the symptoms, both physical and 
emotional, of PME in women with psychiatric comorbidities. Additionally, the current studies do not 
explore the effect of psychiatric comorbidities on premenstrual symptom severity, perceived stress, 
quality of life, healthy lifestyle and wellness self-perception among women with PME and psychiatric 
comorbidities.  
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TABLE 2.1: Overview of Studies Related to PME and Psychiatric Comorbidities 
Author(s) 
Year/Country 
Psychiatric 
Symptoms 
Sample & Setting Research Design 
& Data Analysis 
 
Summary of findings  Study Limitations 
Benavente 
Martin et al 
2010 Spain 
Depression 74 outpatients 
 
48 with PME 
 
26 without PME 
 
Mental health units 
in Vigo, Spain 
 
 
Comparative  
Case Control  
 
Logistic 
Regression  
Analysis 
Women with PME 
experienced higher rates 
of seasonal depression 
(49.2%) than those 
without PME (22.2%; 
P=0.008) 
 
Retrospective assessment of 
premenstrual exacerbation 
 
Only studying personality of 
women who improved may 
have led to bias 
 
DeRonchi et al 
2005 Italy 
Depression 128 reproductive 
age women 
 
43 with late luteal 
phase dysphoric 
disorder (LLPD) 
 
85 with no LLPD 
 
Outpatient 
OB/GYN service 
of Ravenna, Italy 
 
 
Prospective 
Controlled Trial  
 
Logistic 
Regression 
Analysis  
Women with moderate 
symptoms of depression 
were more likely to 
experience LLPD (OR 
1.9; P<0.001) compared 
to women without LLPD 
 
LLPD is likely to 
represent a variant of 
depressive disorder 
Potential selection bias 
(inadequate recruitment & 
self-referral) 
 
Assessments were not 
performed during luteal phase 
of menstrual cycle  
LLPD is likely to represent a 
variant of a Depressive 
Disorder where premenstrual 
changes exacerbate depressive 
symptoms 
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Forrester-
Knauss et al 
2011 
Switzerland 
Depression 3,518 population-
based sample of 
Women, age <55, 
without 
hysterectomy 
 
2,848 healthy  
413 with PMS 
197 with MDD 
60 with PMS + 
MDD 
 
Data from Swiss 
Health Service 
Survey 2007 
 
Cross-sectional 
Case Control 
 
Logistic 
Regression 
Analysis 
 
35.9% of women with 
PME also experience 
MDD (X2=11.58; P < 
0.01). Women with 
medium & high 
psychological distress 
showed higher odds of 
suffering from MDD  
(OR, 1.68 and 3.32, 
respectively; P=<0.001)  
Cross-sectional design yielded 
inability to deduce causal 
relationships 
Self-report measures 
Richards et al 
2006 USA 
Depression 105 women with 
menstrual cycle 
irregularities 
 
70 depressed 
 
35 non-depressed 
 
Menopause Clinic 
of the National 
Institute of Mental 
Health 
Comparative 
Cross-Sectional 
Case Control 
 
Prospective 
Correlational 
Analysis 
Higher proportion of 
menstrual related 
symptom cyclicity & 
premenstrual dysphoria 
was observed in depressed 
women 
 
Significantly higher 
proportion of women with 
depression met criteria for 
comorbid premenstrual 
dysphoria than non-
depressed women (21% vs 
3%; P = 0.04) 
 
Peri-menopause may alter 
course of premenstrual 
dysphoria 
 
Self-reporting 
 
Liberal diagnostic criteria may 
have overestimated the 
frequency of occurrence of 
both menses-related symptom 
cyclicity & premenstrual 
dysphoria 
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Choi et al 
2011 Korea 
Bipolar 
Disorder 
183 reproductive age 
women 
 
61 with bipolar I or 
II disorder 
 
122 healthy controls 
 
Inpatient & 
outpatient Samsung 
Medical Center, 
Seoul, Korea 
Comparative 
Cross-Sectional 
Case Control 
 
Retrospective 
Correlational 
Analysis 
Women with bipolar 
disorder experience 
seasonal & premenstrual 
changes in mood & 
behavior regardless of 
their bipolar episodes 
 
PME was significantly 
higher (74.9%) in patients 
with Bipolar disorders 
compared to controls 
(19.7%) (P=0.001) 
 
 
Self-reporting 
 
Retrospective evaluation 
 
Psychiatric treatments might 
unevenly influence PMS 
Dias et al 
2011 USA 
 
 
Bipolar 
Disorder 
293 reproductive 
age women with 
bipolar disorder 
191+ PME  
102- PME 
 
Systematic 
Treatment 
Enhancement 
Program for 
Bipolar Disorder-
multiple sites 
 
Comparative Cross 
Sectional Case 
Control 
 
Longitudinal 
Retrospective  
Correlational 
Analysis 
Women with bipolar 
disorder & PME had more 
episodes and depressive 
symptoms than women 
with Bipolar without PME 
 
Interference with 
work/school (78.1% vs 
23.7%; P<0.001) 
 
Increased Depression 
(34.3% vs 14.1%; P<0.01) 
 
Increased Bipolar 
Episodes (46.1% vs 
32.4%; P=0.04) 
 
Retrospective reporting of 
mood symptoms in relation to 
menstrual cycle 
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Fornaro & 
Perugi 
2010 Italy 
Bipolar 
Disorder 
 
92 reproductive 
age women with 
Bipolar I or II 
Disorder 
 
25 with PMDD 
 
67 without PMDD 
 
San Martino 
University 
Hospital of Genoa, 
Italy & its 
facilities 
 
Comparative Case 
Control  
 
Retrospective 
Correlational 
Analysis 
 
PMDD is a frequent co-
morbid condition among 
women with Bipolar II 
Disorder (88% vs 60%) as 
well as  
Cyclothymic disorder 
(72% vs 36%; P=0.002) 
Post-partum 
Depression(36% vs 
14.9%; P=0.026) 
Obsessive Compulsive 
disorder (24% vs 7.5%; 
P=0.03) Body 
Dysmorphic Disorder 
24% vs 6%; P=0.01) 
 
Limited sample size 
 
Retrospective reporting of 
symptoms 
 
Study conducted as part of 
routine clinical service may 
have contributed to bias 
Karadag et al 
2004 Turkey  
Bipolar 
Disorder 
69 reproductive 
age women  
 
34 with bipolar 
disorder prescribed 
mood-stabilizers, 
such as: Lithium or 
Valproate 
 
35 healthy controls 
 
3 mood disorder 
outpatient units in 
Istanbul, Turkey 
Retrospective 
Comparative 
Cross-Sectional 
Case Control 
 
Logistic 
Regression 
Analysis 
Menstrual cycle effect 
was present in both 
groups, though healthy 
controls experienced more 
PME in depressive, 
anxiety & attention 
symptoms compared with 
women treated for Bipolar 
(M=175.3, SD=60.2 vs 
M=218.2, SD=69.9, 
respectively 
U = 385.5; P<0.05) 
 
 
Limited sample size 
 
Observation of subjects only 
over 2 month period 
 
Exclusion of patients on 
psychotropic drugs other than 
mood stabilizers 
 
Results are only generalizable 
to women with Bipolar 
Disorder who have responded 
to Lithium or Valproate 
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Portella, 
Haaga & 
Rohan 
2006 USA 
Seasonal 
Affective 
Disorder 
 
91 college females 
with PME 
 
18 with SAD 
29 Subsyndromal- 
SAD (S-SAD) 
30 non depressed 
14 unclassified 
 
American 
University, 
Washington, DC 
 
Comparative Cross 
Sectional 
 
Correlational 
Analysis 
High correlation between 
PME and seasonality  
(r = 0.45; P<0.001)  
Time of assessment was not 
standardized with respect to 
season or menstrual phase 
 
Retrospective reporting 
 
Ko, Long, 
Chen, Chen, 
Huang & Yen 
2013 Taiwan 
Depression, 
Irritability 
& Anxiety 
 
67 women with 
PMDD 
 
75 healthy 
controls  
 
Kaosiung Medical 
University 
Hospital, Taiwan 
Prospective 
Comparative 
Controlled Trial 
 
Logistic 
Regression 
Analysis 
 
Symptoms of depression, 
anxiety & hostility are 
exacerbated in women 
with PMDD (t=6.036 vs 
t=0.836; t=6.314 vs 
t=1.170 & t=5.897 vs 
t=0.405, respectively; 
P<0.001) but not in those 
without PMDD.  
 
Women with irritability 
during PME experienced 
more functional 
impairment (0.34 vs 0.23; 
P<0.01) than women 
without PMDD 
 
 
Single study with small 
sample size 
 
PMDD diagnosis based on 
diagnostic interview  
 
Co-morbidity of PMDD with 
depression or anxiety was no 
controlled in the analysis 
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Hsiao, Hsiao 
& Liu 2004 
Taiwan 
MDD 
GAD 
PD 
SCZ 
200 women with 
regular menses 
 
50 MDD 
50 GAD 
50 Panic Disorder 
(PD) 
50 Schizophrenia 
(SCZ) 
 
Chang Gung 
Medical Center, 
Taiwan 
 
Comparative cross 
sectional  
 
Logistic 
Regression  
Analysis 
Psychiatric disorders-
GAD (52%), MDD 
(52%), PD (36%) and 
SCZ (20%) (X2=18.4, 
d.f.=3; P<0.005)-were 
highly correlated with 
PME 
 
Symptom overlap may 
contribute to over-reporting of 
symptoms attributed to the 
premenstrual phase 
 
Retrospective reporting 
 
KEY:  LLPD = Late Luteal Phase Dysphoric Disorder; PMS = Premenstrual Syndrome; MDD = Major Depressive Disorder;  
            PME = Premenstrual Exacerbation; SAD = Seasonal Affective Disorder; PMDD = Premenstrual Dysphoric Disorder;  
            GAD = Generalized Anxiety Disorder; PTSD = Post-traumatic Stress Disorder; PD = Panic Disorder;  
 SCZ = Schizophrenia; S-SAD = Subsyndromal Seasonal Affective Disorder
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Conceptual Framework   
 The conceptual framework of the Diathesis-Stress Model guided the current research 
study (refer to Figure 2.1). Using the Diathesis-Stress Model, a biopsychosocial model for 
psychopathology (Zuckerman, 1999), psychiatric disorders (depression, anxiety, and 
bipolar) present as a diathesis or stressor that contributes to greater premenstrual symptom 
severity and perceived stress and a lower healthy lifestyle in women with PME.  Comorbid 
psychiatric disorders and PME may also lead to significantly reduced levels of quality of life 
and lower levels of wellness self-perception. Women of reproductive age who experience 
PME with and without psychiatric comorbidity serve as an ideal population with which to 
apply the Diathesis Stress Model. Whether a woman experiences PME with or without 
psychiatric comorbidities, this Diathesis-Stress Model will offer a schema to understand 
how psychiatric comorbidities affect premenstrual symptom severity, perceived stress, 
healthy lifestyle, quality of life and wellness self-perception. 
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FIGURE 2.1: Diathesis-Stress Model of Comorbid Psychiatric Disorders and PME        
          Stressors        Consequences 
   
 
Summary 
 This chapter explored the relevant studies on PME, biological factors, perceived stress, 
healthy lifestyle, quality of life, and wellness self-perception among women experiencing PME with 
and without psychiatric disorders. Although the majority of these studies examined PME in healthy 
women of reproductive age, they did find a correlation between psychiatric illness and PME. The 
research reviewed identified depression, anxiety, seasonal affective disorder and bipolar symptoms 
as the most common psychiatric comorbidities with PME. The findings also reveal the gap in 
knowledge, where the effect of psychiatric comorbidities on premenstrual symptom severity, 
perceived stress, quality of life, healthy lifestyle and wellness self-perception are largely unknown. 
Psychiatric  
Comorbidity
PME
- Increased Severity of PME Symptoms 
- Increased Perceived Stress
- Decreased Reported Healthy Lifestyle
- Decreased Reported Quality of Life
- Decreased Reported Wellness Self-Perception                    
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Clinical Implications 
 This integrative review of the literature indicates the need for research on women 
experiencing PME and psychiatric comorbidities. Both of these conditions can significantly affect 
quality of life and wellness self-perception. Given that there is a marked overlap in the symptoms of 
PME and psychiatric disorders, clinicians who treat women must be aware of and evaluate the 
nature and timing of the symptom presentation in order to identify women at risk for more severe 
premenstrual symptoms.  
 The majority of research studies related to PME focus on the symptoms, stress, 
psychosocial factors and quality of life among women without psychiatric comorbidities.  
No studies could be located that describe the effect of comorbid psychiatric symptomatology 
on premenstrual symptom severity, perceived stress, healthy lifestyle, quality of life and 
wellness self-perception in women with PME. Additionally, there are no studies that 
specifically compare the effects of PME and premenstrual symptom severity between 
women with and without comorbid psychiatric disorders. None of the studies were designed 
as a comparative descriptive study, which is the ideal method for examining the differences 
between these two populations of women. Finally, no studies were found to be conducted by 
nurses nor were any published in the nursing literature. This study adds to the scientific and 
nursing literature by not only defining the population of women experiencing PME and 
psychiatric comorbidities but also comparing the experience of these women to the 
experience of women with PME and no psychiatric comorbidities  
The Diathesis-Stress Model provides the ideal conceptual framework to guide this 
comparative descriptive study comparing premenstrual symptom severity between women 
experiencing PME with and without psychiatric comorbidities. Chapter 3 defines the 
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methodological approach to compare premenstrual symptom severity, perceived stress, 
quality of life, healthy lifestyle and wellness self-perception between women with and 
without psychiatric comorbidities, and determine the effect of psychiatric comorbidities 
among women with PME on premenstrual symptom severity, perceived stress, quality of 
life, healthy lifestyle and wellness self-perception.
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Chapter 3: RESEARCH DESIGN and METHODOLOGY 
This chapter defines the methodology to compare premenstrual symptom severity, 
perceived stress, quality of life, healthy lifestyle and wellness self-perception between 
women with and without psychiatric comorbidities, and determine the effect of psychiatric 
comorbidities among women with PME on premenstrual symptom severity, perceived 
stress, quality of life, healthy lifestyle and wellness self-perception. The research approach 
and design are described as well as the populations being compared, the study settings, the 
sample and sampling techniques, instrumentation used to collect the data, data collection 
procedures, and data analysis plan. In addition, this chapter includes a description of 
protection of human subjects and patient confidentiality. 
Research Design 
      This study was conducted using a comparative descriptive design to compare 
premenstrual symptom severity, perceived stress, quality of life, healthy lifestyle, and 
wellness self-perception between women experiencing symptoms of PME with and without 
psychiatric comorbidities, and to determine the effect of psychiatric comorbidities among 
women with PME on premenstrual symptom severity, perceived stress, quality of life, 
healthy lifestyle and wellness self-perception. 
Sample 
 This convenience study sample consisted of two different groups of women.  
Specifically the case group consisted of women who have PME and no psychiatric 
comorbidities and the comparison group consisted of women who experienced PME with 
psychiatric comorbidities (depression, anxiety, bipolar, or other psychiatric disorders). Any 
woman of reproductive years between the ages of 18 years and 55 years who experienced 
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PME with or without psychiatric comorbidities was eligible to participate if she met 
inclusion and exclusion criteria defined below.  
 Sample size. An á priori power analysis was conducted to determine the minimum 
necessary sample size in order to obtain a recommended statistical power of 0.80 (Cohen, J., 
1992). Estimating a medium effect size for an independent groups t test, a sample size of 
fifty-one (51) participants per group was expected to yield the desired statistical power with 
alpha set at 0.05. Estimating a medium to large effect size yielded a recommendation for 
thirty (30) participants per group. Therefore, this study attempted to obtain at least fifty-one 
(51) participants per group in order to improve the chances of detecting differences between 
women with PME who have psychiatric comorbidities and women who have PME but do 
not have psychiatric comorbidities on the study variables of interest.  
Sampling strategy. The subjects participating in this study consisted of a 
convenience sample of study-eligible women recruited from various nursing organization 
databases described below.  
Inclusion criteria. A woman was eligible to participate in the study if she:  
• Was between the ages of 18 years and 55 years 
• Had regular (24 to 35 day) menstrual cycles 
• Experienced premenstrual physical and/or emotional related symptoms  
Women were included in the comparison group based on the above eligibility criteria 
and the presence of psychiatric comorbidities. Women were included in the case group if 
they met the eligibility inclusion criteria above and had no history of a psychiatric disorder, 
such as: depression, anxiety, bipolar, or other disorder.  
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Exclusion criteria. Individuals were excluded from participation in the study if they: 
• Were of male gender 
• Were younger than age 18 years or older than age 55 years  
• Had not experienced regular (24 to 35 day) menstrual cycles 
• Did not experience premenstrual physical and/or emotional related symptoms 
Setting 
Women with PME with and without comorbid psychiatric disorders were recruited 
from various nursing organization membership lists to complete various surveys and rating 
scales, which were available via a secure website www.PremenstrualStudy.com (refer to 
appendices 6, 7, and 8). Registered nurses represent a cross-section of the female population, 
of all ages and all demographics; there are almost 2.7 million nurses employed in the United 
States and over ninety (90%) percent are women (Bureau of Labor Statistics, 2013). The 
membership lists of the following nursing organizations were utilized to recruit study 
participants for both the case and control groups: 
• Division of Consumer Affairs, New Jersey State Board of Nursing (NJBON) 
• New Jersey State Nurses Association (NJSNA) 
• American Psychiatric Nurses Association (APNA) 
• Association of Women's Health, Obstetric and Neonatal Nurses (AWHONN) 
• University of Pennsylvania-School of Nursing 
• Drexel University-College of Nursing 
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Recruitment 
Study participants were recruited from each database by sending a "blast" email, 
including the study notice and the recruiting flyer (Appendices 4 and 5, respectively), to the 
membership announcing the study and/or by posting an announcement of the study on the 
membership discussion board via the organization's website. If the individual consented 
(refer to Appendix 9 to view the study informed consent) to participate, she then continued 
to complete the Premenstrual Study Prescreening Questionnaire (refer to Appendix 10). 
Upon meeting the inclusion criteria for either the case group (PME without psychiatric 
comorbidities) or the comparison group (PME with psychiatric comorbidities), study 
participants were able to complete the remaining confidential Socio-Demographic 
Questionnaire and study surveys (refer to Appendices 11 through 16). Participation in the 
study was voluntary and consent could have been withdrawn at any time. The initial 
recruitment began in August 2015 and ended in early October 2015.  
Data Collection Procedures  
All potential participants received a website link (Appendices 6, 7 and 8) directing 
them to the study consent and questionnaires, which were developed using Drexel 
University's Qualtrics online survey software (Qualtrics Version 12,018, Provo, UT, 2015). 
The participant surveys, code and data analysis used for this study were generated using 
Qualtrics software. Data was collected from August 2015 to October 2015).  
If interested, subjects completed the Informed Consent Form Appendix 9), and a 
brief Pre-screening Survey (Appendix 10). The six question pre-screening survey 
determined the woman's eligibility to participate in the study. Upon meeting eligibility 
requirements, those participants who identified themselves as experiencing psychiatric 
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comorbidities (depression, anxiety, obsessive compulsive disorder, attention deficit disorder, 
etc.) were entered into the comparison group, and those who did not identify themselves as 
experiencing psychiatric comorbidities were entered into the case group.  
The participants were then directed to the study surveys, including: a Socio-
Demographic Questionnaire, the Premenstrual Symptoms Screening Tool (PSST), the 
Perceived Stress Scale (PSS), the Quality of Life Scale (QOLS), the Healthy Lifestyle 
Questionnaire (HLQ) and the Wellness Self-Perceptions Scale (WSPS) (appendices 11 
through 16, respectively). Each questionnaire and survey consisted of approximately 15 
questions and required approximately 10 minutes to complete. A study participant could 
anticipate a total time allotment of 45 to 60 minutes to complete the surveys included in the 
study. Study participants had one week to submit their surveys and responses after 
consenting to the study. Data collection was completed on October 1, 2015. 
Measures 
Socio-demographics. Socio-demographic information was collected to identify the 
characteristics of the study participants including: age, race, educational level, occupation, 
hours worked, marital status, history of abuse, household members, gynecologic and 
obstetric history, major medical illnesses, nutrition and lifestyle status. This information was 
collected using the Socio-Demographic Questionnaire (Appendix 11), developed by the 
study investigator.  
Premenstrual Symptoms Screening Tool. The physical symptoms of PME include: 
lethargy, fatigue, increased appetite, weight gain, sleep disruption, breast tenderness or 
swelling, bloated sensation, headache, and joint or muscle pain. The emotional symptoms of 
PME are defined as depressed feelings, anxiety, mood swings or sensitivity, anger or 
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irritability, diminished interest in activities, reduced productivity or participation, relational 
difficulties, inefficiency, feeling overwhelmed, poor concentration and lack of energy. The 
Premenstrual Symptoms Screening Tool (PSST) (Steiner, Macdougall & Brown, 2003) was 
used to measure premenstrual symptom severity. Premenstrual symptom severity is rated on 
a 4-point scale ranging from 0 (not at all) to 3 (severe). The PSST can be accessed by 
referring to Appendix 12.  
 According to Steiner and colleagues (2003), "the PSST reflects DSM-IV criteria and 
'translates' categorical criteria into a rating scale with degrees of severity."(p. 4). Questions 
one through fourteen refer to premenstrual symptom severity with a score ranging from 0 
(Not at All) to 3 (Severe) with a maximum score of 42. A score of 0 to 14 would indicate 
mild PME. A score of 15 to 28 would indicate moderate PME. A score of 29 to 42 would 
indicate severe PME. The benefits of using the PSST over the 'gold standard' of prospective 
daily symptom charting was the ability to establish quickly if a woman meets the criteria for 
PME. This tool served as a starting point for identifying women with PME and the severity 
of their symptoms. Figure 3.1 illustrates Premenstrual Symptom Severity ratings based on 
the PSST. 
The PSST has been translated into various languages for international use in 
detecting premenstrual symptom severity. In 2011, Bentz, Steiner and Meinlschmidt 
reported the reliability of a German version of the PSST to have a Cronbach's alpha of 0.924 
and also concluded that the German version of the PSST was a valid tool to improve the 
identification of women requiring treatment for premenstrual symptoms. Hariri, Banaem, 
Bazi, Malehi and Montazeri (2013) found the reliability of the PSST to be internally 
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consistent with a Cronbach's alpha coefficient of 0.93 and the content to be valid with a 
CVR of 0.7 and CVI of 0.8 on the Iranian version of the scale.  
FIGURE 3.1: Premenstrual Symptom Severity Rating Chart  
 
Rating PME Symptom Severity Scores 
Mild 0-14 
Moderate 15-28 
Severe 29-42 
 
Perceived Stress Scale. Stress, defined as unexpected occurrences contributing to 
feelings of loss of control, inability to cope, lack of confidence, anger and nervousness, was 
measured using the Perceived Stress Scale (Cohen, 1983) which rates each potential area of 
stress on a 5-point scale ranging from 0 (never) to 4 (very often). The PSS can be accessed 
by referring to Appendix 13.  
The PSS (Cohen, 1983) was used to collect perceived stress data from both the case 
and comparison groups. The ten questions in the PSS are simple and easy to understand and 
lack content specific to any specific subpopulation, making it a general tool to rate thoughts 
and feelings contributing to perceived stress over the course of the last month. Validity has 
been demonstrated with higher PSS scores associated with failure to quit smoking, failure to 
control blood glucose levels among diabetics, increased vulnerability to depressive 
symptoms, and increased rates of ‘cold’ symptoms (Cohen & Williamson, 1988). Validity 
has not been demonstrated in women with PME; however, an Arabic version has been 
validated among pregnant and postpartum women (Chaaya, Osman, Naassan & Mahfoud, 
2010).  In this study of pregnant and postpartum Arabic women, the PSS was found to have 
a Cronbach's alpha of 0.74.  
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Scoring of the Perceived Stress Scale ranges from 0 (Never) to 4 (Very Often) with a 
maximum score of 40. A score of 0 to 13 would indicate a mild level of perceived stress. A 
score of 14 to 26 would indicate a moderate level of perceived stress. And a score of 27 to 
40 would indicate a severe level of perceived stress. Figure 3.2 illustrates the Perceived 
Stress Severity ratings. 
FIGURE 3.2: Perceived Stress Severity Rating Chart  
 
Rating Perceived Stress Scores 
Mild 0-13 
Moderate 14-26 
Severe 27-40 
 
Quality of Life Scale. Quality of life is defined as an individual’s level of 
satisfaction with various aspects of their life. Such aspects include: material comforts, 
financial security, physical health, relationships with family and friends, organizational 
involvement, occupational demands, knowledge base, self-understanding, creativity, 
socialization, relaxation, and level of independence. Measurement was conducted using the 
Quality of Life Scale (QOLS) (Flanagan, 1978), which rates each aspect on a 7-point Likert 
scale from 0 (terrible) to 6 (delighted) (Burckhardt & Anderson, 2003). The QOLS can be 
accessed by referring to Appendix 14.  
The Quality of Life Scale (QOLS) (Flanagan, 1978) is a 16-item rating scale, which 
explores satisfaction with home, health, relationships, and social activities (Burckhardt, 
Woods, Schultz & Ziebarth, 1989; Burckhardt, Clark, & Bennett, 1993). The QOLS has 
been validated across various patient populations with chronic illness and diseases; though, 
it has not been utilized to evaluate the quality of life among women with PME. 
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Initial reliability studies for the QOLS were conducted on patients with diabetes, 
rheumatoid arthritis, and post-ostomy surgery. The Cronbach's alpha ranged from 0.82 to 
0.92 and found the QOLS to be a valid and reliable measure of the effect of health and 
disease on quality of life (Burckhardt & Anderson, 2003). Scoring of the Quality of Life 
Scale ranges from 0 (Terrible) to 6 (Delighted) with a maximum score of 96. A score of 0 to 
31 would indicate a "terrible" quality of life; a score of 32 to 63 would indicate a "mixed 
level of satisfaction" with quality of life; and a score of 64 to 96 would indicate that the 
woman is "delighted" with her quality of life. Figure 3.3 illustrates the Quality of Life 
ratings. 
FIGURE 3.3: Quality of Life Rating Chart  
 
Rating Quality of Life Scores 
Delightful 64-96 
Mixed Satisfaction 32-63 
Terrible 0-31 
 
Healthy Lifestyle Questionnaire. Healthy lifestyle is defined as "an active process 
of becoming aware of and making choices toward a health and fulfilling life” (WHO, 1948, 
p. 100). By utilizing the Healthy Lifestyle Questionnaire (HLQ) (Corbin & Welk, 2008), 
women could identify their current behaviors and determine if they are contributing to 
health, wellness and fitness. The thirty questions contained in the HLQ cross eleven lifestyle 
domains, some of which pose health risks, others of which may have an impact on the 
individual's personal habits and environment. The questions are answered by responding 
Yes = 1 or No = 0 to the various questions. The overall sum of the lifestyle domain scores 
offers an indicator of healthy lifestyle behaviors. 
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While the reliability and validity of the HLQ have yet to be conclusively defined, as 
the original purpose of the HLQ was to assess the individual's personal lifestyle behaviors, 
the information can offer insights into the attitudes of women with PME toward their 
adaptation of a healthy lifestyle. The HLQ is available in Appendix 15. This scale is scored 
based on the overall number of "Yes" responses with a maximum of 30. A score of 26 to 30 
indicates an overall positive healthy lifestyle; a score of 20-25 indicates a moderately 
healthy lifestyle, while a score of less than 20 indicates an unhealthy lifestyle in need of 
changes to improve overall health. Figure 3.4 illustrates the Healthy Lifestyle Ratings.  
This questionnaire also contains eleven subscales. While the overall rating offers a 
reasonable indicator for healthy lifestyle behaviors, the subscales do not all pose the same 
degree of risk and should therefore, be viewed with a degree of caution (Corbin & Welk, 
2008). For instance, a score of 3 of 4 on the "avoiding destructive habits" subscale may 
indicate overall health behaviors, yet the individual may use tobacco or other substances 
which have an immediate negative effect on health and wellness (Corbin & Welk). 
FIGURE 3.4: Healthy Lifestyle Rating Chart  
 
Rating Healthy Lifestyle Scores 
Positive Healthy Lifestyle 26-30 
Moderately Healthy Lifestyle 20-25 
Unhealthy Lifestyle < 20 
 
Wellness Self-Perceptions Scale. Wellness is defined as "a state of being that is 
influenced by healthy lifestyles” (Corbin & Welk, 2008, p. 14). The Wellness Self-
Perception Scale (WSPS) (Corbin & Welk, 2008) assesses five dimensions of wellness: 
emotional, intellectual, physical, social and spiritual, which result in an overall 
comprehensive wellness score. The fifteen items are scored using a 4-point Likert scale with 
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'1' indicating that the individual strongly disagrees and '4' indicating that the woman strongly 
agrees with the statement. The information derived from this scale provides insights into 
how women with PME and comorbid psychiatric disorders perceive wellness across the 
various domains compared to women with PME without comorbid psychiatric disorders, 
and whether or not PME and/or psychiatric disorders contribute to wellness self-perception. 
Because the WSPS was originally developed for personal use, the reliability and validity of 
this scale has not been conclusively defined. The WSPS can be accessed by referring to 
Appendix 16. 
The WSPS contains five individually scored wellness dimensions including: 
emotional/mental, intellectual, physical, social and spiritual. The individual wellness 
dimensions scores range from 1 to 12; whereas, the overall comprehensive wellness score 
ranges from 15 to 60.  Refer to Figure 3.5 for the Wellness Self-Perception Rating Chart 
(Corbin & Welk, 2008). 
 
FIGURE 3.5: Wellness Self-Perception Rating Chart  
 
Rating Comprehensive Wellness Scores 
High-level wellness 50-60 
Good wellness 40-49 
Marginal wellness 30-39 
Low-level wellness Below 30 
 
Data Analysis  
 Prior to data analysis, data was entered into the database and reviewed twice. Data 
was then cleaned, coded, and assessed for shape of distribution and normative outliers. Data 
was first analyzed descriptively to offer readers a thorough description of the sample both in 
terms of demographics and how the participants scored on the measures used in the study. 
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Missing data was analyzed using multiple imputation; whereby, all available data from the 
subject was used for analyses. "Multiple imputation accounts for missing data by restoring 
not only the natural variability in the missing data, but also by incorporating the uncertainty 
caused by estimating missing data (Wayman, 2003, p. 4)." 
 Analysis included descriptive and inferential statistics to test the hypotheses. A 
variety of statistical tests were used to analyze and describe the data and draw associations 
between the case and comparison groups of women with PME. A bivariate correlation was 
also run to determine any significant correlations among the study variables. Finally, the 
student's t test and stepwise multiple regressions were run to test the research hypotheses. 
Descriptive statistics. Data pertaining to frequencies, percentages, standard 
deviation and mean percentages comprised the descriptive statistics. The socio-demographic 
data were summarized and compiled into tables to describe the various characteristics of the 
case group and the comparison group of women participating in the study. Chi-Square 
analysis was used to determine whether or not a relationship existed between the case and 
comparison groups on categorical demographic, menstrual, stress and healthy lifestyle 
characteristics. Pearson's Correlation Coefficients were utilized to determine significant 
associations among continuous study variables including: premenstrual symptom severity, 
perceived stress, quality of life, healthy lifestyle, wellness self-perception, diet, exercise, 
number of hours sleep and caffeine intake. 
Inferential Statistics. Inferential statistics were utilized to test the study hypotheses.    
Each of the hypotheses involved comparing women with PME who have psychiatric 
comorbidities to women with PME who do not have psychiatric comorbidities. An unpaired 
t-test was utilized to compare the study outcome variables: premenstrual symptom severity, 
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perceived stress, quality of life, healthy lifestyle and wellness self-perceptions between 
women experiencing PME with and without comorbid psychiatric disorders. Stepwise 
multiple regression was used to determine whether or not the study hypotheses were 
supported.  The ad hoc analysis of the effect of type of birth control on premenstrual 
symptom severity was conducted using an Analysis of Variance (ANOVA). 
Statistical testing for specific AIMS and research hypotheses 
1. Compare PME symptom severity between women with and without psychiatric 
comorbidities. 
 a. Hypothesis: Women with PME and psychiatric comorbidities would experience 
 greater premenstrual symptom severity than women without psychiatric 
 comorbidities. 
b. Statistical test: The student's t test was used to compare differences between groups 
and stepwise multiple regression was used to predict the effect of psychiatric 
comorbidity on premenstrual symptom severity. Four covariates were entered in the 
first step (diet, exercise, sleep and caffeine),  followed by psychiatric comorbidity in the 
second step (reported as a yes/no dichotomous variable). The level of significance was 
set at alpha = 0.05. 
2. Compare perceived stress among women with PME with and without psychiatric 
comorbidities.  
 a. Hypothesis: Women with PME and psychiatric comorbidities would experience 
 greater perceived stress than women with PME without psychiatric 
 comorbidities. 
 b. Statistical test: The student's t test was used to compare differences between  
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 groups and stepwise multiple regression was used to predict the effect of 
 psychiatric comorbidities on the level of perceived stress among women with 
 PME. Four covariates were entered in the first step (diet, exercise, sleep and 
 caffeine), followed by psychiatric comorbidity in the second step (reported as a 
 yes/no dichotomous variable). The level of significance was set at alpha = 0.05. 
3. Compare quality of life among women with PME with and without psychiatric 
comorbidities. 
 a. Hypothesis: Women with PME and psychiatric comorbidities would experience 
 a reduced quality of life compared to women with PME without psychiatric 
 comorbidities.  
 b. Statistical test: The student's t test was used to compare differences between  
groups and stepwise multiple regression was used to predict the effect of psychiatric 
comorbidities on quality of life among women with PME. Four covariates were 
entered in the first step (diet, exercise, sleep and caffeine), followed by psychiatric 
comorbidity in the second step (reported as a yes/no dichotomous variable). The 
level of significance was set at alpha = 0.05. 
4. Compare healthy lifestyle among women with PME with and without psychiatric 
comorbidities. 
 a. Hypothesis: Women with PME and psychiatric comorbidities would experience 
 a less healthy lifestyle than women with PME without psychiatric comorbidities. 
b. Statistical test: The student's t test was used to compare differences between 
groups and stepwise multiple regression was used to predict the effect of 
psychiatric comorbidities on healthy lifestyle levels  among women with PME. 
    
 
    
   
 
 
51
Four covariates were entered in the first step (diet, exercise, sleep and caffeine), 
followed by psychiatric comorbidity in the second step (reported as a yes/no 
dichotomous variable). The level of significance was set at alpha = 0.05. 
5. Compare wellness self-perception among women with PME with and without psychiatric 
comorbidities. 
 a. Hypothesis: Women with PME and psychiatric comorbidities would 
 experience lower levels of wellness self-perception compared to women with 
 PME without psychiatric comorbidities. 
b. Statistical test: The student's t test was used to compare differences between 
groups and stepwise multiple regression was used to predict the effect of 
psychiatric comorbidities on levels of wellness self- perception among women 
with PME. Four covariates were entered in the first  step (diet, exercise, sleep 
and caffeine), followed by psychiatric comorbidity in the second step (reported 
as a yes/no dichotomous variable). The level of significance was set at alpha = 
0.05. 
Protection of Human Subjects and Confidentiality 
 Drexel University institutional Review Board. Prior to recruiting subjects, 
collecting data and conducting the study, permission was obtained from Drexel IRB. The 
Drexel University IRB approval letter, protocol and application are available in Appendices 
1, 2 and 3, respectively.  
 Study participant risks. The potential risks to the women who consented to 
participate in this study were minimal. This study did not involve treatment or interventions, 
but rather the gathering of information provided by the participant’s responses to the various 
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rating scales. The most prominent risks for the research participant related to the time 
involved in completing the various questionnaires and survey forms. These risks were 
considered more ‘risks of convenience’ or ‘nuisance risks,’ as opposed to risks of discomfort 
or side effects. Additional risks may have included feelings of discomfort related to the 
content of some of the questions, as they were of a unique and personal nature. 
 Study participant benefits. The benefit of a subject’s participation included the 
satisfaction the participant may have experienced by contributing to the nursing knowledge 
base related to the experience of PME in both women with and without psychiatric 
comorbidities and the understanding that information obtained through this study may 
enhance the scientific and nursing literature and guide and inform novel interventions and 
treatment guidelines for women who experience PME and psychiatric comorbidities. 
Informed consent procedures. The purpose, risks and benefits of participation were 
explained in writing to all potential study participants. Those women who agreed to 
participate in the study electronically signed a HIPAA-compliant consent form approved by 
the Drexel University IRB. (Refer to Appendix 9). Subjects were informed that their 
participation was strictly voluntary and that they could withdraw their consent to participate 
at any time. There were no negative ramifications for any woman who decided to 
withdrawal her consent to participate in the study. All participants were provided with the 
email and phone contact information of the study investigators as well as the Drexel 
University IRB. 
 Protection against risks. Every effort was made to ensure participant confidentiality 
throughout the study and upon study completion. In order to protect participants against the 
risk of a breach in confidentiality, a unique identifier was assigned to each of the 
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participants. No personally identifying information was collected on study participants. All 
data collected throughout the study was maintained in the HIPPA-compliant, Qualtrics 
secure database. No Internet provider (IP) addresses were collected or stored at any time 
during the participant's engagement in the study, unless the participant voluntarily provided 
her Internet email address to receive the e-gift card as compensation for being one of the 
first 100 subjects to complete and submit the questionnaires. Access to the Qualtrics 
database remained limited to this doctoral candidate and her dissertation committee chair 
and statistician. 
 Inclusion of women and minority subjects. This study included female and 
minority subjects, but did not include male subjects.  
 Inclusion of children. All participants in this study were at least 18 years of age. 
Children under the age of 18 years were excluded from this study. 
 Data and safety monitoring plan. The study did not implement a Phase I, II or III 
clinical trial, so a formal data and safety monitoring plan was not proposed.  
 Compensation of subjects. The first 100 study participants who consented and 
voluntarily provided their email address and completed and submitted the questionnaires and 
surveys in their entirety received a $10 (ten dollar) e-gift card for Amazon™ or Starbucks™. 
The e-gift cards were distributed within 6 weeks of the completion of data collection.   
 Vertebrate animals. No animals were used in any portion of this study. 
Research Team. The research team for this study consisted of:  
 Laura G Leahy, DrNP(c), APRN, PMH-CNS/FNP, BC, Doctoral Candidate, 
DrNP Program Drexel University College of Nursing and Health Professions, Family 
Psychiatric Advanced Practice Nurse.   
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 Bobbie Posmontier, PhD, APRN, CNM, PMH-FNP, BC, Dissertation Chair, 
Associate Professor, Drexel University College of Nursing & Health Professions 
 Owen Montgomery, MD, Dissertation Committee Member,  
Chair, Department Obstetrics & Gynecology, Drexel University School of Medicine.  
 Al Rundio, PhD, DNP, APRN, CARN-AP, NEA-BC, DPNAP, Dissertation 
Committee Member, Associate Dean for Post Licensure & Doctoral Nursing Programs, 
Drexel University College of Nursing & Health Professions 
 Carl Goodrich, PhD, Statistical Consultant, Professor, Fairleigh Dickinson 
University 
 Simon Moon, PhD, Statistical Consultant, Associate Professor, LaSalle University. 
 
Summary 
 This study compared the differences in premenstrual symptom severity, perceived 
stress, quality of life, healthy lifestyle and wellness self-perceptions between women 
experiencing PME with and without comorbid psychiatric disorders. In addition this study 
predicted the effect of psychiatric comorbidities on premenstrual symptom severity, 
perceived stress, healthy lifestyle, quality of life and wellness self-perception among women 
with PME with and without psychiatric comorbidities. This study may inform novel 
interventions and treatment guidelines to achieve optimal symptom management reduce 
perceived stress and improve quality of life, healthy lifestyle and wellness self-perception 
among women with PME and comorbid psychiatric disorders.  
 This chapter described the design of the study, research methodology, study 
population, setting, data collection procedures and data analysis. The protection of human 
subjects and confidentiality of collected data were also included in this chapter. The goal of 
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this study was to gain an understanding of these phenomena of interest, expand the nursing 
and scientific literature and inform nursing practice related to PME and the effect of 
psychiatric comorbidities and PME on premenstrual symptom severity, perceived stress, 
quality of life, healthy lifestyle and wellness self-perception among women across the 
reproductive lifespan. Results of this comparative descriptive design study are presented in 
Chapter 4. 
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Chapter 4: ANALYSIS and RESULTS of the RESEARCH DATA 
 This chapter presents the results of the data collected from the completed online 
Qualtrics surveys of female nurses experiencing PME with and without psychiatric 
comorbidities. Completed survey data was exported from Qualtrics into IBM SPSS® 
Statistics Version 23, the statistical analysis software utilized to complete the data analysis. 
 Data Analysis Procedures 
The data was reviewed twice, cleaned, coded, and assessed for shape of distribution 
and outliers. The demographics of the study sample were described through descriptive 
statistics. A correlational matrix was constructed to explore the associations among all 
variables. Independent samples t-tests and /or chi square tests were used to determine 
differences in demographics, premenstrual symptom severity, perceived stress, quality of 
life, healthy lifestyle and wellness self-perception among women with and without 
psychiatric comorbidity. Stepwise multiple regression was used to test the hypotheses and 
predict the effect of psychiatric comorbidity on premenstrual symptom severity, perceived 
stress, quality of life, healthy lifestyle and wellness self-perception. This study contained 
minimal missing data as analyzed and used multiple imputation to address any missing data. 
Finally the internal reliability of the instruments--Premenstrual Symptom Screening Tool, 
Perceived Stress Scale, Quality of Life Scale, Healthy Lifestyle Questionnaire and the 
Wellness Self-Perceptions Scale--were presented. 
Description of the Study Sample 
 The study yielded 203 responses to the prescreening questionnaire from August 5, 
2015 to October 1, 2015. Upon screening for eligibility, 122 women met the eligibility 
criteria to complete the surveys (Figure 4.1). Fifty-two subjects were entered into the case 
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group of women experiencing PME with no psychiatric comorbidities and seventy subjects 
were entered into the comparison group of women experiencing PME with psychiatric 
comorbidities. Of the individuals who were found ineligible to complete the surveys, four 
individuals were male, 28 did not experience any PME, 32 did not menstruate on a regular 
(24-35 day) cycle, two were under the age of 18 years, two were over the age of 55 years, 
and 13 chose not to complete the full prescreening questionnaire. 
FIGURE 4.1: Flowchart of Study Enrollment 
 
 
 
 
 
 
Total Responses 
N=203
Male 
N=4
Female      
N=199
Irregular Cycle 
N=32
No PME N=28
Incomplete  
Prescreening 
N=13
<11 &/or >55 
Years Old N=4
Met Prescreening 
Criteria         
N=122
Enrolled in          
Case Group            
NO Psychiatric  
Comorbidities   
N=52
Enrolled in 
Comparison Group 
WITH Psychiatric 
Comorbidities   
N=70
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Descriptive Statistics 
 Demographic characteristics. Table 4.1 compares the demographics among women 
with PME and no psychiatric comorbidity (Case) and women with PME and psychiatric 
comorbidity (Comparison). There were significant differences between groups on race and 
pregnancy rate. Specifically, there were more white women in the comparison group 
compared to the case group (94% vs. 85%; Χ2=4.40; P=0.04), and a higher pregnancy rate in 
the comparison group versus the case group (73% vs. 69%, Χ2=28.25; P<0.001) 
 There was no significant difference in age (P=0.19), and participants in both groups 
ranged in age from 18 years to 49 years. The majority of women in each group were between 
the ages of 35 years and 49 years (case 56% vs comparison 57%). There were no significant 
differences in marital status (married, P=0.46, single, P=0.20, divorced, P=0.37). A majority 
of study participants in each group were married (case 81% vs comparison 70%). In addition, 
there were no significant differences in geographic location (urban, P=0.40, suburban, P=0.20, 
rural, no P value). Most women lived in suburban areas (case 52% vs comparison 51%). 
Finally there were no significant differences in education (high school/GED, no P value; 2 year 
degree, P=0.51; 4 year degree, P=0.14; and Masters/Doctorate, P=0.30). Most of the women in 
each group held a minimum of a 4-year degree in nursing or master's/doctorate degree in 
nursing (37% vs 41% and 39% vs 38%, respectively). 
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TABLE 4.1: Demographic Characteristics 
 
Figure 4.2 illustrates the various psychiatric comorbidities experienced by the women 
in the comparison group consisting of women with PME and psychiatric comorbidities. Fifty-
two (74%) of the 70 women who reported experiencing psychiatric comorbidities described 
having at least one mental health condition. Anxiety and Depressive Disorders were reported 
 
Characteristics Case  
(- PMH)  
N=52 (100%) 
Comparison  
(+ PMH)  
N=70 (100%) 
 
Χ2 
 
P value 
Age (years)     
18-34 21(30) 30 (43) 1.59 0.21 
35-49 29 (56) 40 (57) 1.75 0.19 
     
Race     
White 44 (85) 66 (94) 4.40 0.04** 
Black 2 (4) 3 (4) --- --- 
Other 4 (8) 1 (2) --- --- 
     
Marital Status     
Single 4 (8) 14 (20) 1.64 0.20 
Married 42 (81) 49 (70) 0.53 0.46 
Divorced 4 (8) 7 (10) 0.82 0.37 
 
Pregnancy     
Yes 36 (69) 51 (73) 28.25 <0.001** 
     
Location     
Urban 22 (42) 28 (40) 0.72 0.40 
Suburban 26 (50) 36 (51) 1.61 0.20 
Rural 2 (4) 6 (9) --- --- 
     
Education     
High School/GED 0 (0) 5 (7) --- --- 
2 year degree 12 (24) 9 (13) 0.43 0.51 
4 year degree 18 (35) 28 (41) 2.17 0.14 
Masters/Doctorate 19 (37) 26 (38) 1.09 0.30 
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by a majority of the women in the comparison group (N = 37, 53%, respectively); and 
Personality/other disorders were reported by 23% percent. Ten (14%) of the women who 
experienced PME and psychiatric comorbidities reported a diagnosis of Post-Traumatic Stress 
Disorder, nine (13%) reported being diagnosed with Attentional disorders, eight (11%) 
reported a diagnosis of Obsessive-Compulsive Disorder, seven (10%) reported a diagnosis of 
Bipolar Disorder, six (9%) reported being diagnosed with Anorexia or Bulimia and three (4%) 
reported a diagnosis of Schizophrenia. 
FIGURE 4.2: Psychiatric Comorbidities N(%) 
 
 Menstrual and birth control characteristics. Table 4.2 compares the menstrual 
and birth control characteristics of the women with PME and no psychiatric comorbidity to 
women with PME and psychiatric comorbidity. Compared to the case group, women in the 
comparison group used more birth control (75% vs 37%; Χ2=5.83; P=0.02).  
Psychiatric Comorbidities
Depressiv e Disorders: 37(53%)
Anxiety Disorder: 37(53%)
Obsessiv e Compulsiv e Disorder: 8(11%)
Bipolar Disorder: 7(10%)
Anorexia/Bulimia: 6(9%)
Schizophrenia: 3(4%)
Attentional Disorders: 9(13%)
Post Traumatic Stress Disorder: 10(14%)
Personality/Other Disorders: 16(23%)
Depressive Disorders Anx iety Disorder Obsessive Compulsive Disorder
Bipolar Disorder Anorex ia/ Bulimia Schizophrenia At tent ional Disorders
Post Traumat ic Stress Disorder Personality/ Other Disorders
meta- chart .com
N=70
Some women reported >1 disorder
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There were no significant differences in menstrual characteristics including age of 
menarche (prior to 11 years, P=0.44; between 12 and 16 years; P=0.11), menstrual 
frequency (28 to 30 days, P=0.35; 24 to 27 days, P=0.35; 31 to 35 days, P=0.11), bleeding 
time (1 to 4 days, P=0.26; greater than 5 days. P=0.17), and menstrual flow (light, no P 
value; moderate, P=0.09; heavy, P=0.43).  
 The majority of women in both groups began menstruating between the ages of 12 
years and 16 years (case 63% vs comparison 66%). A majority of women in each group 
menstruated on a 28 to 30 day schedule (67% vs 60%), and 25% in each group experienced 
cycles every 24 to 27 days. Two-thirds of the women in each group reported bleeding lasting 
more than five days per cycle (67% vs 66). The majority of women in both groups reported 
their menstrual flow to be in the moderate range (65% vs 69%). 
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TABLE 4.2: Menstrual & Birth Control Characteristics  
 
 Healthy lifestyle characteristics. Table 4.3 compares the healthy lifestyle 
characteristics of women with PME and no psychiatric comorbidities to women with PME  
and psychiatric comorbidities. There were significant differences between women with  
PME and no psychiatric comorbidities and women with PME and psychiatric comorbidities  
on physical health, consuming a healthy diet and hours per day of sleep. Specifically more 
women in the case group considered themselves to be physically healthy and consumed a 
healthy diet compared to the comparison group (Case 92% vs.%; Comparison 80%;  
Χ2=58.06; P<0.001 and 77% vs 50%; Χ2=6.45; P=0.01). More women in the comparison  
 
Characteristics 
Case  
(-PMH)  
N=52 (100%) 
Comparison 
(+PMH)   
N=70 (100%) 
 
Χ
2 
 
P value 
 
Age at Menarche (years)     
Before 11 18 (37) 23 (34) 0.61 0.44  
12 to 16 31 (63) 45 (66) 2.58 0.11  
      
Frequency of Menses (days)     
24-27  12 (25) 17 (25) 0.86 0.35  
28-30  33 (67) 41 (60) 0.87 0.35  
31-35  4 (8) 10 (15) 2.57 0.11  
      
Days Bleeding      
1-4  16 (33) 23 (34) 1.26 0.26  
 >5  33 (67) 45 (66) 1.85 0.17  
      
Menstrual Flow      
Light 6 (12) 6 (9) --- ---  
Moderate 32 (65) 47 (69) 2.85 0.09  
Heavy  11 (23) 15 (22) 0.62 0.43  
      
Birth Control      
Yes 18 (37) 51 (75) 5.83 0.02**  
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group reported sleeping greater than eight hours per day compared to the case group (18%  
vs 8%; Χ2=4.00; P=0.05). While not a significant difference, more women in the comparison 
group also reported sleeping less than six hours per day as compared to women in the case 
group; this result was trending toward statistical significance (35% vs 25%; Χ2=3.46; P=0.06). 
 Consumption of cups of caffeinated beverages per day was not statistically different 
between the groups (0 to 2 cups, P=0.29; >3 cups, P=0.21). There were no significant 
differences between groups on the numbers of days exercised for 30 minutes per day (P=0.45).  
Table 4.3: Healthy Lifestyle Characteristics 
 
Characteristics 
Case  
(- PMH) 
N=52 (100%) 
Comparison  
(+ PMH) 
N=70 (100%) 
 
Χ
2 
 
P value 
Physically Healthy    
Yes 44 (92) 53 (80) 58.06 <0.001** 
     
Healthy Diet     
Yes 37 (77) 33 (50) 6.45 0.01** 
     
Cups per Day of Caffeine     
None- 2  32 (67) 41 (63) 1.11 0.29 
> 3  16 (33) 24 (37) 1.60 0.21 
     
Days per Week of 30 Minutes Exercise   
 M(SD) M(SD) T test P value 
 3.71(1.74) 3.25(1.93) -1.31 0.45 
     
Hours per Day of Sleep     
< 6 12 (25) 23 (35) 3.46 0.06 
6 - 8 32 (67) 31 (47) 0.02 0.90 
> 8 4 (8) 12 (18) 4.00 0.05** 
 
 A breakdown of the medical comorbidities reported by each group of women can be found 
in Figures 4.3 and 4.4, respectively. Women in the comparison group reported more medical 
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comorbidities and lower physical health compared to women in the case group (X2=58.06; 
P=0.00). Fifty-two percent of women in the case group reported no medical comorbidities,  
while only twenty percent of women in the comparison group reported no medical comorbidities. 
 The medical comorbidities reported by women with PME and psychiatric comorbidities 
included: obesity, asthma, migraine headache/pain, cardiac problems/hypertension, gastro-
intestinal, and thyroid disorders (27%, 24%, 24%, 21%, 21% and 11%, respectively). Many of the 
women with PME and psychiatric comorbidities reported having more than one medical 
comorbidity. The medical comorbidities reported by the women in the case group included 
migraine headache/pain, thyroid disorders, cardiac problems/hypertension, obesity, gastro- 
intestinal problems, and asthma (17%, 13%, 12%, 8%, 6% and 2%, respectively). 
FIGURE 4.3: Case Group Medical Comorbidities 
 
 
CASE GROUP Health Issues N (%)
None : 27(52%)
Asthma : 1(2%)
Cardiac : 6(12%)
Obesity : 4(8%)
Thyroid : 7(13%)
Gastro-Intestinal : 3(6%)
Migraine/Pain : 9(17%)
None Asthma Cardiac Obesity Thyroid Gastro- Intest inal
Migraine/ Pain
meta- chart .com
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FIGURE 4.4: Comparison Group Medical Comorbidities 
 
 Stress characteristics. Table 4.4 compares the stress characteristics of women with 
PME and no psychiatric comorbidities to women with PME and psychiatric comorbidities. 
There were statistical differences between the case group and comparison group on type of 
abuse, relationship quality and the time of day women worked. Specifically, more women in 
the comparison group reported being sexually abused than women in the case group (39% vs 
19%; Χ2=6.25; P=0.01). More women in the comparison group worked between the hours of 
5pm and 7am than women in the case group (28% vs 10%; X2=8.17; P<0.001). More women 
with PME and psychiatric comorbidities reported 'unsatisfactory' relationship quality compared 
to women with PME and no psychiatric comorbidities (13% vs 4%; Χ2=4.46; P=0.04). While 
this was a statistically significant finding between the groups, the N was quite small 
(comparison = 9 vs case = 2); thus results should be interpreted with caution.  
COMPARISON GROUP Health Issues N (%)
None : 14(20%)
Asthma : 17(24%)
Cardiac : 15(21%)
Obesity : 19(27%)
Thyroid : 8(11%)
Gastro-Intestinal : 15(21%)
Migraine/Pain : 17(24%)
None Asthma Cardiac Obesity Thyroid Gastro- Intestinal
Migraine/ Pain
meta- chart .com
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 Being a victim of all forms of abuse was not statistically significant between groups. 
While there was no statistically significant difference, most women in both groups were 
satisfied (includes satisfied, excellent and delightful) with the quality of their current 
relationship (case, 96% vs. comparison, 72%).  
 The number of hours worked per week was not statistically significant between 
groups. A moderate number of women with PME and psychiatric comorbidities worked less 
than thirty (30) hours per week or greater than 40 hours per week (comparison 21% vs case 
20%; P=0.32 and 36% vs 33%; P=0.21, respectively); whereas, 47% of the case group versus 
43% of the comparison group worked between 31 and 40 hours per week (P=0.41). A 
majority of both groups worked between the hours of 7am and 5pm (case 90% vs comparison 
72%; P=0.60).
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Table 4.4: Stress Characteristics 
 
Characteristics Case                   
(- PMH)      
N=52 (100%) 
Comparison 
(+ PMH) 
N=70 (100%) 
 
Χ2 
 
P value 
Victim of Abuse    
Yes 14 (29) 37 (55) 1.69 0.19 
     
Type of Abuse     
Physical 7 (44) 8 (24) 0.07 0.80 
Sexual 3 (19) 13 (39) 6.25 0.01** 
Emotional 6 (28) 12 (36) 2.00 0.16 
     
Relationship Quality    
Miserable 0 (0) 6 (9) --- --- 
Unsatisfactory 2 (4) 9 (13) 4.46 0.04** 
Satisfactory 19 (39) 24 (35) 0.58 0.45 
Excellent 19 (39) 20 (29) 0.03 0.87 
Delightful 9 (18) 9 (13) --- --- 
 M(SD) M(SD) T test P value 
 3.06(1.38) 3.29(1.94) 0.717 0.475 
     
# of Hours Worked per Week         
< 30  10 (20) 15 (21) 1.00 0.32 
31-40  23 (47) 29 (43) 0.69 0.41 
> 40  16 (33) 24 (36) 1.60 0.21 
     
Time Worked    
7am to 5pm 44 (90) 49 (72) 0.27 0.60 
5pm to 7am 5 (10) 19 (28) 8.17 <0.001** 
 
Bivariate Correlations 
 Table 4.5 illustrates the bivariate correlations that were run on all variables to assess 
for the presence of significant positive and negative correlations. The following significant 
correlations showed significance at the P = 0.01 level, unless otherwise noted. Non-
significant correlations were not reviewed here. 
 Premenstrual symptom severity was positively correlated with perceived stress (0.62) 
and psychiatric comorbidities (0.27), but inversely correlated with a quality of life (-0.44), 
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healthy lifestyle (-0.31), wellness self-perception (-0.38), healthy diet (-0.26) and quality of 
sleep (-0.31). Perceived stress was positively correlated with psychiatric comorbidities 
(0.30), but inversely correlated with quality of life (-0.62), healthy lifestyle (-0.34), wellness 
self-perception (-0.58) and healthy diet (-0.22).  
Quality of life was positively correlated with healthy lifestyle (0.38), wellness self-
perception (0.77) and healthy diet (0.29), but inversely correlated with psychiatric 
comorbidities (-0.20; P=0.05). Healthy lifestyle was positively correlated with wellness self-
perception (0.44), healthy diet (0.47) and exercise (0.28), but inversely correlated with 
psychiatric comorbidities (-0.27) and caffeine consumption (-0.23). Wellness self-perception 
was positively correlated with healthy diet (0.34) and inversely correlated with psychiatric 
comorbidities (-0.38). PME and psychiatric comorbidities inversely correlated with healthy 
diet (-0.27) and healthy diet was positively correlated with exercise (0.42). 
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TABLE 4.5: Bivariate Correlations 
 
NOTES: Pearson Product Moment Correlations are on the diagonal  
 
        * Correlation is significant at the 0.05 level (2-tailed); ** Correlation is significant at the 0.01 level (2-tailed) 
 
     Variable Names: 1= Premenstrual Symptom Severity; 2 = Perceived Stress; 3 = Quality of Life; 4 = Healthy Lifestyle;  
            5 = Wellness Self-Perception; 6 = Psychiatric Comorbidities (0=No; 1= Yes);  
            7 = Healthy Diet (0=No; 1=Yes); 8 = Number of Days per Week with 30 Minutes Exercise;  
            9 = Number of Hours of Sleep per Day; 10 = Number of Cups of Caffeinated Beverages per Day
Variables 1 
Symptoms 
2 
Stress 
3 
QOL 
4 
Lifestyle 
5 
Wellness 
6 
Comorbidities 
7 
Diet 
8  
Exercise 
9 
Sleep 
10 
Caffeine 
1 1          
2 0.62** 1         
3 -0.44** -0.62** 1        
4 -0.31** -0.34** 0.38** 1       
5 -0.38** -0.58** 0.77** 0.44** 1      
6 0.27** 0.30** -0.20* -0.27** -0.38** 1     
7 -0.26** -0.22** 0.29** 0.47** 0.34** -0.27** 1    
8 -0.01 -0.03 0.04 0.28** 0.07 -0.12 0.42** 1   
9 -0.31** -0.11 0.10 0.06 0.01 0.03 -0.11 -0.08 1  
10 0.09 0.13 -0.13 -0.23* -0.11 0.07 -0.16 -0.06 -0.09 1 
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Comparison of Groups on Major Study Variables 
 Table 4.6 illustrates the differences found in premenstrual symptom severity, 
perceived stress, healthy lifestyle, quality of life, and wellness self-perception between the 
case and the comparison groups. Premenstrual symptom severity was significantly greater in 
the comparison group of women with PME and psychiatric comorbidities compared to the 
case group of women with PME and no psychiatric comorbidities (M=36, SD=9.16 vs 
M=30.53, SD= 10.7; T=0.27; P=0.005). Perceived stress was significantly greater in the 
comparison group compared to the case group (M=22.79, SD=6.18 vs M=18.81, SD=6.67; 
T=0.30; P=0.002). Women with PME and psychiatric comorbidities reported a significantly 
lower quality of life compared to women with PME and no psychiatric comorbidities 
(M=56.63, SD=16.11 vs M=63.49, SD=16.87; T= -0.20; P=0.035). Women in the 
comparison group reported a less healthy lifestyle compared to women in the case group 
(M=36.70, SD=3.92 vs M=39.98,SD=4.07; T= -0.27; P=0.005). Finally, women with PME 
and psychiatric comorbidities had a statistically significant lower level of wellness self-
perception compared to their peers with PME and no psychiatric comorbidities (M=41.44, 
SD=6.47 vs M=47.18, SD=7.85; T= -0.38; P<0.001).  
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TABLE 4.6: Comparison of Groups on Major Study Variables 
 
 Psychiatric 
Comorbidities 
N Mean  Standard 
Deviation 
T 
 Test 
P Value 
 
Symptoms 
 
Yes 
No 
 
63 
47 
 
36.00 
30.53 
 
9.16 
10.71 
 
0.27 
 
0.005** 
 
Stress 
 
Yes 
No 
 
63 
47 
 
22.79 
18.81 
 
6.18 
6.67 
 
0.30 
 
0.002** 
 
Quality of Life 
 
Yes 
No 
 
63 
45 
 
56.63 
63.49 
 
16.11 
16.87 
 
-0.20 
 
0.035* 
 
Healthy Lifestyle 
 
 
Yes 
No 
 
44 
63 
 
36.70 
38.98 
 
 
3.92 
4.07 
 
 
-0.27 
 
0.005** 
 
Wellness 
Self-Perception 
 
Yes 
No 
 
62 
44 
 
41.44 
47.18 
 
6.47 
7.85 
 
-0.38 
 
<0.001** 
Key: Symptoms = Premenstrual Symptom Severity; Stress = Perceived Stress  
Analysis of Specific AIMS 
 This section and Tables 4.7 to 4.11 present results as they pertain to each 
individual study hypothesis using stepwise multiple regression. For all variables the 
level of significance was set at alpha = 0.05. 
 Hypothesis 1. It was hypothesized that women with PME and psychiatric 
comorbidities would experience greater premenstrual symptom severity than women with 
PME without psychiatric comorbidities. The student's t test compared the differences 
between groups described above, and stepwise multiple regression was used to determine the 
effect of psychiatric comorbidities on the severity of PME. Four covariates (diet, exercise, 
sleep and caffeine) were entered in the first step followed by psychiatric comorbidity in the 
second step (reported as a yes/no dichotomous variable). Analysis revealed that poor diet and 
sleep quality significantly predicted increased premenstrual symptoms severity in both steps 
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(β= -0.35; T= -3.51; P<0.001 vs β= -0.34; T= -3.82, P<0.001 and β= -0.29; T= -2.95; 
P<0.001 vs β= -0.34; T= -3.94; P<0.001, respectively) and contributed to nineteen percent of 
the variance on premenstrual symptom severity. Psychiatric comorbidity significantly 
predicted premenstrual symptoms severity in the second step and contributed to an additional 
four percent of the variance (β=0.22; T=2.45; P=0.02). Thus the hypothesis was supported. 
(Refer to Table 4.7). 
TABLE 4.7: Stepwise Multiple Regression on Premenstrual Symptom Severity 
 
Model 
 Unstandardized 
Coefficients 
Standardized 
Coefficients 
T 
Test 
P  
Value 
R2 
Change 
1  B Std 
Error 
Beta    
      
 
Diet -7.21 2.06 -0.35 
 
-3.51 
 
<0.001** 
 
 
Exercise 0.58 0.53 0.11 1.09 0.28 
 
 
Sleep -4.49 1.18 -0.34 -3.82 
 
<0.001** 
 
Caffeine 0.04 1.23 0.00 0.03 0.97 
 
      
0.19 
 
2        
 
Diet -6.07 2.06 -0.29 -2.95 
 
<0.001** 
 
 
Exercise 0.59 0.52 0.11 1.14 0.26 
 
 
Sleep -4.53 1.15 -0.34 -3.94 
 
<0.001** 
 
Caffeine -0.10 1.20 -0.01 
 
-0.08 0.94 
 
 
Psychiatric 
Comorbidities 
 
4.46 
 
1.82 
 
0.22 
 
2.45 
 
 
0.02** 
 
       
0.04 
 
    
 
    
   
 
 
73
  
 Hypothesis 2. It was hypothesized that women with PME and psychiatric 
comorbidities would experience higher levels of perceived stress than women with PME 
without psychiatric comorbidities. The student's t test compared the differences between 
groups described above, and stepwise multiple regression was used to determine the effect 
of psychiatric comorbidities on the level of perceived among women with PME. Four 
covariates (diet, exercise, sleep and caffeine) were entered in the first step, followed by 
psychiatric comorbidity in the second step (reported as a yes/no dichotomous variable). 
Analysis revealed that poor diet predicted higher levels of perceived stress and contributed 
to eight percent of the variance in step one, but was not significant in step two (β= -0.26; T= 
-2.44; P=0.02 vs β= -0.19; T= -1.80; P=0.07). Psychiatric comorbidity significantly 
predicted higher levels of perceived stress in the second step and contributed to an additional 
six percent of the variance on perceived stress (β=0.25; T=2.61; P=0.01). Thus, this 
hypothesis was supported. (Refer to Table 4.8).  
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TABLE 4.8: Stepwise Multiple Regression on Perceived Stress 
 
Model 
 Unstandardized 
Coefficients 
Standardized 
Coefficients 
T 
Test 
P 
Value 
R2 
Change 
1  B Std Error Beta    
      
Diet 
-3.52 1.44 -0.26 -2.44 
     
0.02** 
 
Exercise 
0.27 0.37 0.08 0.73 0.47 
 
Sleep 
-1.12 0.83 -0.13 -1.35 0.18 
 
Caffeine 0.79 0.89 0.09 0.89 0.38 
 
      
0.08 
2 
       
Diet 
-2.61 1.45 -0.19 -1.80 
 
0.07 
 
 
Exercise 0.27 0.36 0.08 0.75 0.46 
 
 
Sleep -1.14 0.81 -0.13 -1.41 0.16 
 
Caffeine 0.61 0.87 0.07 0.71 0.48 
 
 
Psychiatric 
Comorbidities 
3.35 1.29 0.25 2.61 
 
0.01** 
 
       0.06 
  
 Hypothesis 3. It was hypothesized that women with PME and psychiatric 
comorbidities would experience lower levels of quality of life compared to women with 
PME without psychiatric comorbidities. The student's t test compared the differences 
between groups described above, and stepwise multiple regression was used to determine 
the effect of psychiatric comorbidities on quality of life among women with premenstrual 
symptom exacerbation. Four covariates (diet, exercise, sleep and caffeine) were entered in 
the first step, followed by psychiatric comorbidity in the second step (reported as a yes/no 
dichotomous variable). Analysis revealed that healthy diet significantly predicted quality of 
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life in both steps, (β=0.33; T=3.23; P<0.001 vs β=0.30; T=2.81; P=0.01) and contributed to 
twelve percent of the variance. Psychiatric comorbidity did not significantly predict quality 
of life in the second step (β= -0.13; T= -1.28; P=0.20). Low power may have precluded 
detecting the effect of psychiatric comorbidities on quality of life in women with PME since 
this study was not powered on stepwise multiple regression. This hypothesis was not 
supported. (Refer to Table 4.9) 
TABLE 4.9: Stepwise Multiple Regression on Quality of Life 
 
Model 
 Unstandardized 
Coefficients 
Standardized 
Coefficients 
T 
Test 
P 
Value 
R2 
Change 
1  B Std 
Error 
Beta    
Diet 
11.52 3.56 0.33 3.23 
 
<0.001** 
 
Exercise 
-0.82 0.92 -0.09 -0.90 0.37 
 
Sleep 
2.63 2.04 0.12 1.23 0.20 
 
Caffeine -1.67 
 
2.21 -0.07 -0.76 0.45 
 
      
0.12 
2 
       
Diet 
10.32 3.67 0.30 2.81 
 
0.01** 
 
Exercise 
-0.83 0.92 -0.09 -0.91 0.36 
 
Sleep 
2.66 2.04 0.12 1.31 0.20 
 
Caffeine 
 
-1.51 2.21 -0.07 -0.68 0.50 
 
 
Psychiatric 
Comorbidities 
 
-4.21 
 
3.29 
 
-0.13 
 
-1.28 
0.20 
 
  
     
0.01 
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Hypothesis 4. It was hypothesized that women with PME and psychiatric 
comorbidities would experience a less healthy lifestyle than women with PME without 
psychiatric comorbidities. The student's t test compared the differences between groups 
described above, and stepwise multiple regression was used to determine the effect of 
psychiatric comorbidities on healthy lifestyle level among women with PME. Four covariates 
(diet, exercise, sleep and caffeine) were entered in the first step, followed by psychiatric 
comorbidity in the second step (reported as a yes/no dichotomous variable). Analysis 
revealed that a healthier diet, more days per week of exercise and less caffeine intake 
significantly predicted a positive healthy lifestyle in both steps, (Step 1: diet β=0.26; T=2.70; 
P=0.01, exercise β=0.28; T=2.90; P=0.01 and caffeine β= -0.22; T= -2.56; P=0.01 vs Step 2: 
β=0.23; T=2.35, P=0.02; β=0.27; T=2.86, P=0.01 and β= -0.22; T= -2.50, P=0.01, 
respectively). A healthier diet, more days per week of exercise and less caffeine intake 
contributed to twenty-nine percent of the variance on healthy lifestyle, while psychiatric 
comorbidity did not significantly predict healthy lifestyle in the second step (β= -0.13; T= -
1.43; P=0.16). This hypothesis was not supported. (Refer to Table 4.10). 
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TABLE 4.10: Stepwise Multiple Regression on Healthy Lifestyle 
 
Model 
 Unstandardized 
Coefficients 
Standardized 
Coefficients 
T 
Test 
P 
Value 
R2 
Change 
1  B Std Error Beta    
      
Diet 
2.18 0.81 0.26 2.70 
 
0.01** 
 
Exercise 0.61 
0.21 0.28 2.90 
 
0.01** 
 
Sleep 
0.42 0.45 0.08 0.92 0.36 
 
Caffeine -1.25 0.49 -0.22 
 
-2.56 0.01** 
 
      
0.29 
2 
       
Diet 
1.93 0.82 0.23 2.35 
 
0.02** 
 
Exercise 
0.60 
 
0.21 0.27 2.86 
 
0.01** 
 
Sleep 
0.41 0.45 0.08 0.91 0.37 
 
Caffeine -1.22 0.49 -0.22 
 
-2.50 0.01** 
 
 
Psychiatric 
Comorbidities 
 
-1.01 
 
0.71 
 
-0.13 
 
 
-1.43 
 
0.16 
 
       
0.02 
 
 Hypothesis 5. It was hypothesized that women with PME and psychiatric 
comorbidities would experience lower wellness self-perception compared to women with 
PME without psychiatric comorbidities. The student's t test compared the differences 
between groups described above, and stepwise multiple regression was used to determine the 
effect of psychiatric comorbidities on levels of wellness self-perception among women with 
PME. Four covariates (diet, exercise, sleep and caffeine) were entered in the first step, 
followed by psychiatric comorbidity in the second step (reported as a yes/no dichotomous 
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variable). Analysis revealed that healthy diet significantly predicted wellness self-perception 
in both steps (β=0.38; T=3.65; P<0.001 vs β=0.29; T=2.85; P=0.01) and contributed to 
thirteen percent of the variance on wellness self-perception. Psychiatric comorbidity 
significantly predicted decreased wellness self-perception in the second step and contributed 
to an additional eight percent of the variance on wellness self-perception (β=-0.30; T= -3.14; 
P<0.001). Thus, this hypothesis was supported. (Refer to Table 4.11) 
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TABLE 4.11: Stepwise Multiple Regression on Wellness Self-Perception 
 
Model 
 Unstandardized 
Coefficients 
Standardized 
Coefficients 
T 
Test 
P  
Value 
R2 
Change 
1  B Std 
Error 
Beta    
      
Diet 
5.88 1.61 0.38 3.65 
 
<0.001** 
 
Exercise 
-0.38 0.41 -0.09 -0.84 0.41 
 
Sleep 
0.31 0.93 0.03 0.33 0.74 
 
Caffeine -0.63 1.01 
 
-0.06 -0.62 0.54 
 
      
0.13 
2 
       
Diet 
4.56 1.60 0.29 
 
2.85 
 
0.01** 
 
Exercise 
-0.35 0.40 -0.09 -0.88 0.38 
 
Sleep 
0.35 0.89 0.04 0.39 0.70 
 
Caffeine -0.48 0.97 -0.05 -0.50 0.62 
 
 
Psychiatric 
Comorbidities 
-4.53 1.44 -0.30 -3.14 
 
<0.001** 
 
       0.08 
 
Internal Reliability of Study Instruments 
All study instruments were found to be reliable. The Cronbach’s alphas for the rating 
scales utilized in this study were as follows: Premenstrual Symptoms Screening Tool (PSST) 
was found to be 0.93; Perceived Stress Scale (PSS) was found to be 0.82; Quality of Life 
Scale (QOLS) was found to be 0.92; Healthy Lifestyle Questionnaire (HLQ) was found to be 
0.74 and the Cronbach's alpha for the Wellness Self-Perception Scale (WSPS) was found to 
be 0.89. 
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Ad Hoc Analysis 
 In reviewing the menstrual and birth control characteristics (Table 4.2), women with 
PME and psychiatric comorbidities reported using birth control at a statistically significant 
higher rate than women with PME and no psychiatric comorbidities (P=0.02). A breakdown 
of the types of birth control used by women in the case and comparison groups are reflected 
in Figures 4.5 and 4.6, respectively. Hormonal birth control methods included: oral 
contraceptives, hormonal patch, hormonal intrauterine device, hormonal injection and 
hormonal implant. Non-hormonal birth control methods included: condoms, diaphragm and 
non-hormonal intrauterine device.  
 
FIGURE 4.5: Case Group Types of Birth Control 
 
CASE GROUP Type of Birth Control N (%)
No Response : 1(6%)
Hormonal : 9 (50%)
Non-Hormonal : 3(17%)
Tubal Ligation : 5(28%)
No Response Hormonal Non- Hormonal Tubal Ligat ion
meta- chart .com
N = 18 Women who Reported Using Birth Control
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FIGURE 14: Comparison Group Types of Birth Control 
 
 
As certain oral hormonally based contraceptive methods have been utilized as 
treatments for Premenstrual Dysphoric Disorder, further analysis was warranted to 
determine if type of birth control had an effect on premenstrual symptom severity in women 
who reported experiencing PME with and without psychiatric comorbidities. An analysis of 
variance revealed that the type of birth control did not have a statistically significant effect 
on premenstrual symptom severity in either women with PME and no psychiatric 
comorbidities or women with PME and psychiatric comorbidities (F=0.17, P=0.84 vs 
F=0.26, P=0.61, respectively) (Table 4.12). It is important to note that the number of women 
using non-hormonal birth control was very low, and therefore because of low power, results 
of this analysis should be interpreted with caution. 
COMPARISON GROUP Type of Birth Control N (%)
No Response : 25(49%)
Hormonal : 13(25%) 
Non-Hormonal : 5 (10%)
Tubal Ligation : 8 (16%)
No Response Hormonal Non- Hormonal Tubal Ligat ion
meta- chart .com
N = 51  Women who Reported Using Birth Control
    
 
    
   
 
 
82
TABLE 4.12: Effect of Type of Birth Control on Premenstrual Symptom Severity 
Dependent Variable: Premenstrual Symptom Severity 
Source Type III Sum 
of Squares 
df Mean Square F  
Test 
P 
 Value 
Corrected Model 137.32a 5 27.47 0.29 0.92 
 
Intercept 25207.15  1 25207.15 266.29 0.00 
 
Birth Control 32.58 2 16.29 0.17 0.84 
 
Psychiatric 
Comorbidities 
24.77 1 24.77 0.26 0.61 
 
 
Birth Control * 
Psychiatric 
Comorbidities 
33.74 2 16.87 0.18 0.84 
Error 3218.45 34 94.66 
 
  
Total 50759.00 40 
 
   
Corrected Total 3355.78 39    
KEY: a. R squared = 0.04 (Adjusted R squared = -0.10) 
 
Summary  
 This chapter presented the results of the survey data. The student’s t-test found 
statistically significant differences on premenstrual symptom severity and perceived stress, 
quality of life, healthy lifestyle and wellness self-perception in women with PME and 
psychiatric comorbidity compared to women with PME and no psychiatric comorbidity. The 
student's t test also found that significantly more women with PME and psychiatric 
comorbidities reported being sexually abused, reported working between the hours of 5pm 
and 7am and reported 'unsatisfactory' relationship quality compared to women with PME 
and no psychiatric comorbidities.  
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 Further, in stepwise multiple regression psychiatric comorbidities significantly 
predicted increased premenstrual symptom severity, increased perceived stress, and lower 
levels of wellness self-perception. In addition, poor diet, less days per week of exercise and 
poor sleep quality significantly contributed to the variance on premenstrual symptom 
severity. Analysis of the data also revealed that psychiatric comorbidity in women with 
PME did not predict lower quality of life and a less healthy lifestyle. Ad hoc analysis of 
methods of birth control used by women with PME with and without psychiatric 
comorbidities found that the type of birth control did not have a significant effect on 
premenstrual symptom severity. The final chapter, will summarize the findings of this study, 
compare the results of this study to existing studies in the literature, describe the strengths 
and limitations of the study, offer recommendations for future research and discuss the 
implications for clinical nursing practice.  
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Chapter 5: DISCUSSION, IMPLICATIONS and CONCLUSIONS 
 
 This chapter will summarize the findings presented in Chapter 4, compare the results 
to existing studies in the literature, describe the strengths and limitations of the study, offer 
recommendations for future research and discuss the implications for clinical nursing 
practice.  
Overview of the Study 
 The purpose of this comparative descriptive study was to compare the premenstrual 
symptom severity, perceived stress, healthy lifestyle, quality of life, and wellness-self-
perception among women with PME with and without psychiatric comorbidities. This study 
also determined the effect of psychiatric comorbidity in women with PME on premenstrual 
symptom severity, perceived stress, healthy lifestyle, quality of life and wellness self-
perception. It further explored whether variables such as diet, exercise, quality of sleep and 
caffeine intake had an effect on premenstrual symptom severity, perceived stress, quality of 
life, healthy lifestyle and wellness self-perception among women with PME and psychiatric 
comorbidity. This study provides the critical foundation from which novel treatment 
interventions and symptom management guidelines can be developed for women who 
experience PME and comorbid psychiatric disorders. 
 The study sample consisted of 122 female nurses, ages 18 years to 49 years, who 
experienced regular menstrual cycles and PME. The women were divided into 2 groups: 1) 
women with PME and no psychiatric comorbidities (Case) and 2) women with PME and 
psychiatric comorbidities (Comparison) (N=52 and N=70, respectively).  
 
 
    
 
    
   
 
 
85
Summary of the Study Results  
Comparing the major study variables, the following differences were found between 
women with PME and no psychiatric comorbidities (case group) and women with PME and 
psychiatric comorbidities (comparison group): 1) premenstrual symptom severity was 
significantly greater in the comparison group compared to the case group; 2) perceived 
stress was significantly greater in the comparison group compared to the case group; 3) the 
comparison group reported a significantly lower quality of life compared to the case group; 
4) women in the comparison group reported less healthy lifestyles compared to women in 
the case group and 5) women in the comparison group reported lower levels of wellness 
self-perception compared to women in the case group. 
 Analysis of the specific aims of the study was conducted using stepwise multiple 
regression with the level of significance set at alpha = 0.05. 
 Hypothesis 1: Poor diet and low sleep quality predicted increased premenstrual 
symptom severity in both steps and psychiatric comorbidity predicted premenstrual 
symptom severity in the second step. The study data supported the hypothesis that women 
with PME and psychiatric comorbidities would experience greater premenstrual symptom 
severity than women with PME and no psychiatric comorbidities. 
 Hypothesis 2: Poor diet predicted increased perceived stress in step one, but only 
psychiatric comorbidity predicted increased perceived stress in step two. The research data 
supported the hypothesis that women with PME and psychiatric comorbidities would 
experience higher levels of perceived stress than women with PME without psychiatric 
comorbidities. 
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 Hypothesis 3: A healthier diet significantly predicted a better quality of life in both 
steps, while psychiatric comorbidity did not significantly predict lower quality of life in the 
second step. Low power may have precluded detecting the effect of psychiatric 
comorbidities on quality of life in women with PME because the sample size was not 
powered on multiple regression. The study data did not support the hypothesis that women 
with PME and psychiatric comorbidities would experience a lower quality of life compared 
to women with PME and no psychiatric comorbidities.  
 Hypothesis 4: Healthy diet, more days per week of exercise and less caffeine intake 
significantly predicted healthy lifestyle in both steps; while psychiatric comorbidity did not 
predict healthy lifestyle in step two. The study data did not support the hypothesis that 
women with PME and psychiatric comorbidities would experience a less healthy lifestyle 
than women with PME and no psychiatric comorbidities. 
 Hypothesis 5: Healthy diet significantly predicted higher levels of wellness self-
perception in both steps, while psychiatric comorbidities significantly predicted lower levels 
of wellness self-perception in the second step. The study data supported the hypothesis that 
women with PME and psychiatric comorbidities would experience lower levels of wellness 
self-perception compared to women with PME without psychiatric comorbidities. 
 The results of this study support the hypotheses that when women experience PME 
and psychiatric comorbidities, they will experience increased premenstrual symptom 
severity, increase perceived stress and decreased wellness self-perception. The results of the 
study did not support the hypotheses that women with PME and psychiatric comorbidities 
would experience a less healthy lifestyle and lower quality of life. 
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 Healthy diet predicted lower premenstrual symptom severity and perceived stress 
and higher quality of life, healthy lifestyle and wellness self-perception and poor quality of 
sleep predicted higher premenstrual symptom severity. Increased days per week of exercise 
and decreased caffeine intake predicted a healthier lifestyle. 
 Analysis of the study data indicated that women with PME and psychiatric 
comorbidities also experienced greater medical comorbidities and lower physical health than 
women with PME and no psychiatric comorbidities (X2=58.06; P<0.001). Further 
exploration of this finding is essential because according to the National Comorbidity 
Survey Replication (Alegria, Jackson, Kessler and Takeuchi, 2003), while 25% of the adult 
population suffers from a psychiatric disorder, 68% of adults with psychiatric disorders have 
comorbid medical conditions. An ad hoc analysis of this finding revealed that, although 
women with PME and psychiatric comorbidities reported using more birth control than 
women with PME and no psychiatric comorbidities (P=0.02), the type of birth control did 
not have a statistically significant effect on premenstrual symptom severity in women with 
PME and no psychiatric comorbidities or women with PME and psychiatric comorbidities 
(P=0.61). This finding also warrants further exploration because certain oral hormonally 
based contraceptive methods have been utilized as treatment for PMDD. The study data also 
indicated that more women with PME and psychiatric comorbidities reported being sexually 
abused, working between the hours of 5pm and 7am and reported more 'unsatisfactory' 
relationship quality than women with PME and no psychiatric comorbidities (P=0.01, 
P=0.04 and P<0.001, respectively). 
 In reviewing the health determinants of PME severity, the findings of this study 
support that psychiatric comorbidities predict higher PME severity, healthy diet predicts 
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lower premenstrual symptom severity and poor sleep quality predicts higher PME severity. 
Further, the findings support that a healthy diet predicts lower perceived stress and higher 
quality of life, healthy lifestyle and wellness self-perception, while increased days per week 
of exercise and decreased caffeine intake predicts a healthier lifestyle among women with 
PME with and without psychiatric comorbidities.  
 The Diathesis-Stress Model offered the conceptual framework for this study.  The 
original framework prior to the study predicted that the stressors of PME and psychiatric 
comorbidities would lead to the following consequences: 1) increased premenstrual 
symptom severity, 2) increased perceived stress, 3) lower quality of life, 4) less healthy 
lifestyle and 5) decreased reported wellness self-perception. Figure 5.2 illustrates the 
findings of this study that PME and psychiatric comorbidities predicts increased 
premenstrual symptom severity, increased perceived stress and decreased wellness self-
perception but not quality of life or healthy lifestyle.
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FIGURE 5.2: Diathesis Stress Model of Study Findings 
   Stressors        Consequences 
 
 
Comparison of the Findings to Existing Literature 
 The current literature related to PME in women with psychiatric comorbidities is 
limited, especially as it pertains to the effect of psychiatric comorbidities on premenstrual 
symptom severity, perceived stress, quality of life, healthy lifestyle and wellness self-
perception in women with PME. Additionally, there are no current studies, which compared 
the differences between PME in women with and without psychiatric comorbidity. This 
comparative study on the effect of psychiatric comorbidity on premenstrual symptom 
severity, perceived stress, quality of life, healthy lifestyle and wellness self-perception is a 
first not only for nursing literature but also women's health literature.  
Psychiatric  
Comorbidity
PME
- Increased Severity of PME Symptoms 
- Increased Perceived Stress
- Decreased Reported Wellness Self-Perception                    
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 The results of this study support the findings of a recent study, which found that the 
level of stress and premenstrual symptom severity were significantly higher in women with 
PME and comorbid anxiety and/or depression (Balaha, 2010). In addition the findings of this 
study support another study, which found that women with higher PME severity experience 
higher levels of stress (Lustyk et al, 2004). El-Masry and Abdelfatah (2012) found that 
women with PME experienced a lower quality of life than the healthy female population and 
Lustyk and colleagues (2004) found that PME is associated with poor quality of life; 
however, this study did not support their findings. While t tests found significant differences 
in quality of life between the case and comparison group, psychiatric comorbidity did not 
significantly predict quality of life in stepwise multiple regression.  These conflicting results 
may have occurred, as the study was not powered on multiple regression analysis. 
Additionally, given that the majority of the women in the study were college-educated white 
nurses, a 'ceiling effect' may have occurred, precluding the detection of differences related to 
quality of life in women with PME with and without psychiatric comorbidities. 
 This study which found that psychiatric comorbidities predicted more severe PME, 
supports findings from Richards and colleagues (2006), who found that women with 
depression experienced greater PME severity, and Benavente and colleagues (2010), who 
found that women who experience PME also experience greater rates of seasonal 
depression. The findings of this study also support Choi and colleagues (2011), who studied 
Premenstrual Dysphoric Disorder and Bipolar Disorder and found a majority of the women 
with comorbid psychiatric illness experienced higher rates of PME. In addition, the current 
study supports the findings of Dias and colleagues (2011), who found that PME in women 
with psychiatric comorbidity leads to more frequent bipolar episodes and depressive 
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symptoms compared to women with PME and no psychiatric comorbidity. Many studies in 
the existing literature (Ko, Long, Chen et al, 2013; Karadag et al, 2012; Fornaro and Perugi, 
2010; Benavente, Martin et al, 2010; and DeRonchi et al, 2005) indicate that psychiatric 
symptoms are exacerbated during the luteal phase of the menstrual cycle leading to their 
authors' conclusions that PME and psychiatric disorders can be comorbid conditions; 
however, the studies did not explore the effect of psychiatric comorbidities on premenstrual 
symptom severity, perceived stress, quality of life, healthy lifestyle or wellness self-
perception as in the current study. 
 This study supported the existing literature (Lustyk and Gerrish, 2010 and Negin, 
Fereydoun et al, 2015) that poor diet increases premenstrual symptom severity. The study by 
Negin, Fereydoun and colleagues (2015) found that women with PME who consumed a 
Western diet, as compared to a healthy or Middle Eastern diet, experienced a higher severity 
of PME (P<0.05). This finding warrants further research on women with PME and 
psychiatric comorbidity given the results of this study. Existing literature also found that 
women with PME, who increased their level of exercise, (Lustyk and Gerrish, 2010 and 
Samadi, Taghian and Valiani, 2013) experienced reduced PME severity and levels of stress; 
although they did not examine the effect of psychiatric comorbidities on these variables. 
Similar to Pinar and colleagues (2011), the current study found that increased intake of 
caffeine had a significant negative effect on the healthy lifestyle of women with PME. 
 The results of this study support prior research that women with PMDD reported 
more sexual abuse experiences than healthy controls (P<0.01) (Girdler, Sherwood, 
Hinderliter et al, 2003). Additionally, this study supports Pilver and colleagues' (2011) study 
which found that women who had a history of trauma with or without PTSD were more 
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likely to report PME and PMDD than their peers without a history of trauma (trauma with 
PTSD: PME-AOR=1.97; P<0.001 & PMDD-AOR=8.14; P<0.001 and trauma without 
PTSD: PME-AOR=1.43; P<0.01 & PMDD-AOR=2.84; P<0.05). Although this dissertation 
does not address neurotransmitter levels in relation to PME, Girdler and colleagues' study 
(2003) correlating PME and sexual abuse, also found lower resting norepinephrine levels 
and greater luteal phase norepinephrine reactivity to mental stress (P<0.05 and P=0.01, 
respectively), which may offer the foundation for further pharmacological research to treat 
PME in women with a history of sexual abuse.  
 While it is known that working permanent night shift disrupts the normal diurnal 
rhythm, according to Chung and colleagues (2009), nurses who work permanent night shift 
have higher sympathetic activity than their peers who work day shift.  In addition, another 
recent study found that work stress as defined by shift work might produce or exacerbate 
PME (Jahromi, Pakmehr and Hagh-Shenas, 2011). While this study, which found that more 
women with PME and psychiatric comorbidities worked between the hours of 5pm and 7am 
did not examine the effect of shift work on PME, it is a subject that requires further 
examination to improve treatment interventions for this population of reproductive-age 
women.   
 This study also supports the findings of Halbreich, Borenstein, Pearlstein and Kahn 
(2003) that indicate women with PME and comorbid chronic major depression experience a 
significantly greater impairment in marital and parental relationships compared to the 
community norm of healthy women (P<0.0001 vs P>0.05). Since this study found that 
women with PME and psychiatric comorbidities reported more 'unsatisfactory' relationship 
quality than women with PME and no psychiatric comorbidities, further examination of the 
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factors affecting relationships in women with PME and psychiatric comorbidities is needed 
to guide psychotherapeutic interventions. Finally, Hourani and colleagues (2004) found that 
military women with PME experienced lower levels of wellness self-perception than their 
peers without PME, but their study did not examine the effect of psychiatric comorbidity on 
PME and wellness self-perception. Despite the similarities between the existing literature 
and the current study, there remains a paucity of published literature related to women with 
PME and psychiatric comorbidities and the effect of psychiatric comorbidities on 
premenstrual symptom severity, perceived stress, quality of life, healthy lifestyle and 
wellness self-perception.  
Strengths and Limitations of the Study 
  There are several strengths of this study including that this is the first study 
comparing the effect of psychiatric comorbidity on PME among women of reproductive age 
with and without psychiatric comorbidity. In addition, the number of participants in the 
study was greater than the minimum needed based on power analysis with alpha set at 0.05 
using the student t-test. In addition, there was very little missing data on the surveys. Finally 
this study supports findings in similar studies exploring PME symptoms among women with 
psychiatric comorbidities. The research adds to the knowledge base in psychiatric and 
women's health nursing and defines this unique population of reproductive age women in the 
context of their hormonally induced premenstrual symptom exacerbations. 
  The limitations of the study include that while the majority of the nursing population 
consists of women, nurses may not be wholly representative of the general population of 
women with PME with and without psychiatric comorbidity. The study participants were 
predominantly healthy, White/Caucasian, college-educated nurses, which underrepresents 
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women of other racial. ethnic and educational backgrounds. These factors may have 
contributed to a 'ceiling effect' precluding the detection of effect of psychiatric comorbidities 
in women with PME on quality of life and healthy lifestyle. Further, the study was only 
offered in English, which may have excluded women whose primary language is not English 
or whose command of the written English language is limited. Additionally, the study was 
only available to women who had Internet access via a computer, tablet or smart phone; 
thus, there was no definitive way to determine who might have been responding to the 
surveys. This factor may have also excluded women who did not have access to a computer, 
tablet or smartphone from participating in the study. 
 Although the collected data remained confidential, participants may not have been 
willing to share the sensitive and stigma-laden information pertaining to psychiatric 
disorders, which was necessary to define the comparison group. There are numerous 
similarities between the symptoms of PME and the symptoms of many of the psychiatric 
disorders, including depression, anxiety and bipolar disorders, which may preclude 
discriminating between psychiatric comorbidity and PME. Additionally, despite achieving 
the N suggested by the á priori power analysis with the alpha set at 0.05, the study was not 
powered on regression, which may have limited the findings related to quality of life and 
healthy lifestyle. Finally, while this study provided an ad hoc analysis of the effect of type of 
birth control on PME symptom severity, it did not examine the types of psychotropic 
medications women in the comparison group may be taking or the potential effect of 
psychotropic medications on PME symptoms severity. 
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Recommendations for Future Research  
 Based on the findings of this comparative descriptive study examining the effect of 
psychiatric comorbidities on women with PME, future research can be conducted to build 
upon this database, especially in the nursing literature. A larger scale study open to all 
reproductive age women of varied race and ethnicity, educational experience and housing 
location, as opposed to exclusively nurses, with regular menstrual cycles, who experience 
PME and psychiatric comorbidities, would likely strengthen the current results. A 
replication of this study incorporating the above factors would likely capture greater 
differences in physical health, quality of life and healthy lifestyle. 
 As diet had a significant effect in predicting premenstrual symptom severity, 
perceived stress, quality of life, healthy lifestyle and wellness self-perception, it warrants 
further exploration of optimal foods that mitigate the severity of PME among women with 
psychiatric comorbidities. Additionally, further research is required to identify 
pharmacologic and non-pharmacologic treatments for this population. In the existing 
literature, Karadag and colleagues (2012) found that women with bipolar disorder and 
comorbid PME, who were prescribed the mood stabilizing pharmacological agents Lithium 
and Valproate, experienced significantly less premenstrual exacerbation of psychiatric 
symptoms compared to healthy controls without PME. This is one of the only studies to 
identify potential pharmacologic interventions to relieve premenstrual symptom severity in 
women with psychiatric comorbidities. As this study compared women with PME with and 
without psychiatric comorbidities, it did not examine the effect of potential psychotropic 
medications on PME symptom severity. Future research is needed to examine the effect of 
psychotropic medications on PME symptom severity. 
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 In their study of Iranian nurses with and without PME, Negin, Fereydoun and 
colleagues (2015) found that women who consumed a Middle Eastern as opposed to a 
Western diet, experienced lower severity of PME. Although, this is one of the only studies 
to examine the effect of diet on women with PME, but it does not address women with PME 
and psychiatric comorbidities. In another Iranian study conducted by Samadi, Taghian and 
Valiani (2103, they found that women with PME who exercised experienced a significant 
reduction in severity of PME compared to women with PME who do not exercise. Despite 
these findings in the existing literature, no American studies have been conducted to 
examine the effects of pharmacologic interventions and health and wellness interventions on 
women with PME and comorbid psychiatric disorders. This study can inform future research 
aimed at developing novel pharmacologic and non-pharmacologic interventions, 
psychological interventions and health and wellness interventions to reduce premenstrual 
symptom severity and perceived stress, and improve quality of life, enhance healthy lifestyle 
and improve wellness self-perception in women who experience the PME and comorbid 
psychiatric illness.  
 According to the National Sleep Foundation (2016), individuals who work the 
overnight hours often find it difficult to balance work, sleep and relationships. As the 
findings of this dissertation indicated that more women with PME and psychiatric 
comorbidities reported working between the hours of 5pm to 7am and experiencing 
'unsatisfactory' relationship quality, further research could be conducted to determine the 
effect of sleep hygiene techniques and/or pharmacological sleep aides on reducing PME 
symptom severity as well as improving the quality of relationships in these women.  
Additionally, research on the effect of psychotherapy might be warranted, not only for the 
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women with PME and psychiatric comorbidities who reported more 'unsatisfactory' 
relationship quality compared to women with PME and no psychiatric comorbidities, but 
also for the women with PME and psychiatric comorbidities who reported being sexually 
abused.  While the study findings indicated that more women in the comparison group 
reported being sexually abused compared to women in the case group, the effect of sexual 
abuse on PME symptom severity has not been studied.  
 Given the finding that women with PME and psychiatric comorbidities reported 
experiencing 'unsatisfactory' relationship quality, further research is needed to examine the 
effect of psychoeducation and psychotherapeutic interventions offered to women with PME, 
their partners and extended family members. Finally, additionally research is needed to learn 
whether women with psychiatric comorbidities experience PME and to determine the effect 
of PME on psychiatric symptoms of women with psychiatric comorbidities. 
Implications for Clinical Nursing Practice 
 Nurse practitioners in various healthcare settings, such as psychiatry, primary care, 
and women’s health often interface with women who experience PME and comorbid 
psychiatric disorders. Not only are nurses in advanced practice called upon to treat the 
psychiatric symptoms, but must also manage the overlay of physical and emotional 
symptom dysregulation some women experience due to hormonal oscillation across their 
menstrual cycles. According to the American College of Obstetricians and Gynecologists 
(ACOG, 2003), roughly 85% of women, who experience at least one physical and one 
emotional symptom consecutively across three menstrual cycles, have symptoms severe 
enough to interfere with their daily activities. Additionally, Yang and colleagues (2008) 
found that women with PME experienced negative mental health related quality of life 
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burden which exceeded that of both the general population and that of women with chronic 
back pain and rivaled the burden of women with type II diabetes, osteoporosis, rheumatoid 
arthritis and hypertension. Nurse practitioners, who often use a holistic approach to 
healthcare, will be on the frontlines of treating women who experience premenstrual 
symptom exacerbation and co-occurring psychiatric comorbidities. Nurses can intervene by 
utilizing health and wellness education, sleep hygiene techniques, pharmacological and 
psychotherapeutic modalities to not only reduce PME symptom severity and perceived stress 
but also enhance overall quality of life for women with PME and psychiatric comorbidities.   
Nurses can also provide psychoeducation not only to the women who suffer from PME and 
psychiatric comorbidities but also to male providers and family members who interface with 
these women. 
 The potential effect of hormonally induced mood exacerbations in women with 
comorbid psychiatric disorders has a tremendous significance for the nurse practitioners 
entrusted to provide their care. This study provides the foundation by describing the specific 
phenomena and experiences of this unique population of reproductive age women. The 
findings support that women with PME and psychiatric comorbidities experience greater 
premenstrual symptom severity, increased levels of perceived stress and lower levels of 
wellness self-perception and can inform advanced practice nurses in developing novel 
treatments and interventions to assist this unique population of women throughout their 
reproductive years. 
Conclusions 
  PME with psychiatric comorbidity can significantly affect premenstrual symptom 
severity, perceived stress and wellness self-perception. Given that there is a marked overlap 
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in the symptoms of PME and psychiatric disorders, clinicians who treat women must be 
aware of and evaluate the nature and timing of the symptom presentation in order to identify 
women with psychiatric comorbidity who are at risk for more severe premenstrual 
psychiatric symptoms. This form of assessment may serve to inform the way in which 
practitioners dose and administer novel pharmacologic therapies to women with PME and 
psychiatric comorbidities.  
While psychotherapy, pharmacologic interventions, wellness practices, and healthy 
lifestyle choices have shown to improve the experience of women who experience PME as 
well as those women who independently experience psychiatric illness, this research 
highlights the need to extrapolate and apply those successful therapeutic interventions to this 
unique population of women who experience comorbid PME and psychiatric 
symptomatology. Nurses in advanced practice will most likely treat women who experience 
PME and psychiatric comorbidities. As nurses practice from a holistic perspective, provide 
psychoeducation and encourage lifestyle modifications, the findings of this study serve to 
inform novel psychotherapeutic and pharmacologic interventions and treatment guidelines to 
achieve optimal symptom management, reduce perceived stress and improve wellness self-
perception among women with PME and comorbid psychiatric disorders.
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Appendix 2 
Drexel University IRB 1505003677 Protocol 
 
 
1)    Protocol Title:                                                                                             
The Continuum of Premenstrual Symptom Exacerbation in Women 
With and Without Psychiatric Comorbidities:  
A Nurses' Health Study 
 
2)    IRB Review History 
DOES NOT APPLY 
3)    Objectives 
The purpose of this Nurses' Health Study is to: compare symptom exacerbation, 
perceived life stress, quality of life, healthy lifestyle and wellness-self-
perception among women with Premenstrual Symptom Exacerbation (PME) 
with and without psychiatric comorbidities. 
The specific aims of this study are to: 
 1. Compare severity of PME among women with psychiatric comorbidities to women 
without psychiatric comorbidities. 
      2. Compare perceived life stress among women with PME with and without psychiatric 
comorbidities.  
 3. Compare quality of life among women with PME with and without psychiatric 
comorbidities. 
 4. Compare healthy lifestyle among women with PME with and without psychiatric 
comorbidities. 
 5. Compare wellness self-perception among women with PME with and without 
psychiatric comorbidities. 
 
The Research Hypotheses to be tested are: 
 1. Women with PME and psychiatric comorbidities will experience more severe 
premenstrual symptom exacerbation than women without psychiatric comorbidities. 
 2. Women with PME and psychiatric comorbidities will experience higher levels of 
perceived life stress than women with PME without psychiatric comorbidities. 
 3.  Women with PME and psychiatric comorbidities will experience lower levels of 
quality of life compared to women with PME without psychiatric comorbidities. 
 4. Women with PME and psychiatric comorbidities will experience a less healthy 
lifestyle than women with PME without psychiatric comorbidities. 
 5. Women with PME and psychiatric comorbidities will experience lower wellness self-
perception compared to women with PME without psychiatric comorbidities. 
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4)    Background 
 It is widely known that menstrual cycle fluctuations can significantly impact a woman's 
mood, behavior and quality of life over the course of her reproductive years, largely due to 
reproductive hormonal variations during the course of the menstrual cycle. While only six 
percent of reproductive age women met the DSM-IV-TR (APA, 2000) criteria for premenstrual 
dysphoric disorder (PMDD) it is estimated that approximately eighty percent of women 
experience premenstrual symptom exacerbation (PME) (Pearlstein & Steiner, 2008). A 
majority of women, who experience premenstrual dysphoric disorder, have symptoms, which 
are severe enough to interfere with their daily activities (Ginsburg & Dinsay, 2000).  This 
statistic is highly significant as the reproductive years can span as many as four decades or 
more for some women; thus, if premenstrual symptom exacerbations occur over a span of 
seven days per month, the woman's quality of life is reduced by 3 months per year or greater 
than 10 years over her reproductive life cycle.   
  Little is known, however, about premenstrual symptom exacerbations (PME) and their 
impact on perceived life stress, quality of life, healthy lifestyle and wellness self-perception 
among women with and without psychiatric comorbidities. While it is known that 
retrospectively, 25 to 68 percent (Payne, Roy & Murphy-Eberenz et al, 2007) and 
prospectively, 55 to 65 percent (Angst, Sellaro, Merikangas & Endicott, 2001) of women 
diagnosed with major depressive disorder or bipolar disorder also report premenstrual 
symptom exacerbation, no studies could be located that addressed the difference in symptom 
presentation, perceived life stress, quality of life, healthy lifestyle and wellness self-perception 
between women who experience PME with and without psychiatric comorbidities. 
 The potential impact of hormonally induced mood exacerbations in women with co-
morbid psychiatric disorders has a tremendous significance for the nurse practitioners 
entrusted to provide their care, especially given the lack of literature available on this topic.  
There is certainly a need to further identify and describe this population and the impact that 
PME leaves on the perceived negative life stress, quality of life, healthy lifestyle and wellness 
self-perception of almost 85 percent of the female population (ACOG).  This study will 
provide the foundation by describing these specific phenomena, which will serve to inform 
interventions and treatment guidelines for these women during their reproductive years.  
 
5)    Inclusion and Exclusion Criteria 
 Upon consenting to participate in the study, a six-question survey (see attached 
Prescreening Questionnaire) will determine the participant's eligibility and whether they will 
be assigned to the case group or the comparison group. 
 The subjects participating in this study will consist of a convenience sample of study-
eligible women recruited from various nursing organization databases described below.  
Permission will be obtained from the organizations prior to commencing recruitment. 
Inclusion criteria.  A woman is eligible to participate in the study if she:  
• Is between the ages of 18 and 55 years 
• Has regular (24-35 day) monthly menstrual cycles 
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• Experiences premenstrual physical and/or emotional related symptoms  
A woman will be included in the comparison group based on the above eligibility criteria and 
the absence of psychiatric comorbidities.  A woman will be included in the case group if she 
meets the eligibility inclusion criteria above and has a history of a psychiatric disorder, such 
as: depression, anxiety, bipolar, or other disorder.  
Exclusion criteria. Individuals will be excluded from participation in the study if they: 
• Are of male gender 
• Are younger than age 18 or older than age 55  
• Have not experienced regular (24-35 day) monthly menstrual cycles 
• Do not experience premenstrual physical and/or emotional related symptoms 
ALL of the Following Groups WILL BE EXCLUDED 
• ☐    Adults unable to consent   
• ☐    Individuals who are not yet adults (infants, children, teenagers)  
• ☐    Pregnant women 
• ☐    Prisoners 
• ☐  Not Applicable  
6)    Study-Wide Number of Subjects 
 An a priori power analysis was conducted to determine the minimum necessary sample 
size in order to obtain a recommended statistical power of .80 (Cohen, J., 1992). Estimating 
a medium effect size for an independent groups t test, a sample size of 51 participants per 
group is expected to yield the desired statistical power.  Estimating a medium to large effect 
size yielded a recommendation for 30 participants per group. Therefore, this study will 
attempt to obtain at least 51 participants per group in order to improve the chances of 
detecting differences between women with Premenstrual Symptom Exacerbation (PME) who 
have psychiatric comorbidities and women who have PME but do not have psychiatric 
comorbidities on the study variables of interest.  
 
7)    Study-Wide Recruitment Methods 
 Study participants will be recruited from each database by sending a "blast" email to 
the membership announcing the study and/or by posting an announcement of the study on the 
membership discussion board via the organization's website.. If the individual is eligible to 
participate as either a participant in the case group or the control group, they will receive a 
private, confidential link by which they can access and complete the Informed Consent Form, 
Socio-Demographic Form and study surveys.  Participation in the study is voluntary and 
consent may be withdrawn at any time.     
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 All potential participants will receive a link directing them to Drexel University's 
Qualtrics, where, if interested, they will complete the Informed Consent Form, and a brief 
Pre-screening Survey. The 6-question pre-screening survey will determine the woman's 
eligibility to participate in the study. Upon meeting eligibility requirements, those participants 
who identified themselves as experiencing psychiatric comorbidities (depression, anxiety, 
obsessive compulsive disorder, attention deficit disorder, etc.) will make up the case group, 
those who do not identify themselves as suffering from psychiatric comorbidities will make up 
the comparison group.  
 Refer to attached Advertisement & Prescreening Questionnaire 
 The initial recruitment will begin in June 2015 and continue until September 2015 or 
until a minimum of 51 subjects per group are obtained. 
 
8)     Study Timelines 
 Upon meeting eligibility requirements, those participants who identified themselves as 
experiencing psychiatric comorbidities (depression, anxiety, obsessive compulsive disorder, 
attention deficit disorder, etc.) will make up the case group, those who do not identify 
themselves as suffering from psychiatric comorbidities will make up the comparison group. 
The participants will then be directed to the study surveys, including: a Socio-Demographic 
Questionnaire, the Premenstrual Symptoms Screening Tool (PSST), the Perceived Stress Scale 
(PSS), the Quality of Life Scale (QOLS), the Healthy Lifestyle Questionnaire (HLQ) and the 
Wellness Self-Perceptions Scale (WSPS).   
 Each questionnaire and survey consists of approximately 15 questions and will require 
approximately 10 minutes to complete. A study participant should anticipate a total time 
allotment of 45-60 minutes to complete the surveys included in the study. Study participants 
will have one (1) week to submit their surveys and responses.   
 Study recruitment, enrollment and data collection are anticipated to be completed by 
the end of September 2015.    The estimated date to complete Primary Analyses of this study is 
October 2015. 
9)     Study & Statistical Endpoints 
 1. Compare severity of PME among women with psychiatric comorbidities to women 
without psychiatric comorbidities. 
 a.  Hypothesis: Women with PME and psychiatric comorbidities will experience more 
severe premenstrual symptoms than women without psychiatric comorbidities. 
 b.   Statistical test:  Hierarchical Multiple Regression Analysis will be used to 
determine the  effect psychiatric co-morbidity on symptom severity of premenstrual 
 symptoms. Three covariates will be entered in the first step (diet, exercise and 
 relational stress), followed by psychiatric co-morbidity in the second step (will be 
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reported as a yes/no dichotomous variable).  The level of significance will be set at alpha = 
0.05 
 2. Compare perceived life stress among women with premenstrual symptom 
exacerbation with and without psychiatric comorbidities.  
 a.   Hypothesis:  Women with PME and psychiatric comorbidities will experience 
higher levels of perceived life stress than women with PME without psychiatric comorbidities 
 b.   Statistical test:  Hierarchical Multiple Regression Analysis will be used to measure 
the effect of psychiatric co-morbidities on the level of perceived life stress among women with 
PME.  Three covariates will be entered in the first step (relational stress, occupational 
 stress and lifestyle management), followed by psychiatric co-morbidity in the second 
step (will be reported as a yes/no dichotomous variable). The level of significance will be set 
at alpha = 0.05. 
 3. Compare quality of life among women with PME with and without psychiatric 
comorbidities. 
 a.  Hypothesis:  Women with PME and psychiatric comorbidities will experience 
lower levels of quality of life compared to women with PME without psychiatric comorbidities  
 b.  Statistical test:  Hierarchical Multiple Regression Analysis will be used to 
determine the effect of psychiatric co-morbidities on quality of life among women with 
premenstrual symptom exacerbation. Three covariates will be entered in the first step 
(relational stress, occupational stress and lifestyle management), followed by psychiatric co-
morbidity in the second step (will be reported as a yes/no dichotomous variable). The level of 
significance will be set at alpha = 0.05. 
 4. Compare healthy lifestyle among women with PME with and without psychiatric 
comorbidities. 
 a. Hypothesis:  Women with PME and psychiatric comorbidities will experience a less 
healthy lifestyle than women with PME without psychiatric comorbidities. 
 b. Statistical test:  Hierarchical Multiple Regression Analysis will be used to 
determine the  effect of psychiatric co-morbidities on healthy lifestyle levels among women 
with PME. Three covariates will be entered in the first step (diet, exercise and lifestyle 
management), followed by psychiatric co-morbidity in the second step (will be reported as a 
yes/no dichotomous variable). The level of significance will be set at alpha = 0.05. 
 5.   Compare wellness self-perception among women with PME with and without 
psychiatric comorbidities. 
 a. Hypothesis:  Women with PME and psychiatric comorbidities will experience lower 
wellness self-perception compared to women with PME without psychiatric comorbidities. 
 b. Statistical test: Hierarchical Multiple Regression Analysis will be used to measure 
the effect of psychiatric co-morbidities on levels of wellness self- perception among women 
with PME. Three covariates will be entered in the first step (relational stress, occupational 
stress and lifestyle management), followed by psychiatric co-morbidity in the second step (will 
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be reported as a yes/no dichotomous variable). The level of significance will be set at alpha = 
0.05. 
 
10)    Procedures or Methods Involved 
 This study will be conducted using a case control design comparing the impact of the 
daily PME symptoms, perceived life stress, quality of life, healthy lifestyle, and wellness self-
perception of women experiencing symptoms of PMS/PMDD with and without co-morbid 
psychiatric disorders.  A variety of rating scales will be used to collect data and determine 
what differences, if any, the presence or absence of psychiatric disorders has on many aspects 
of and experiences in the lives of women with PME. 
 All potential participants will receive a link directing them to Drexel University's 
Qualtrics, where, if interested, they will complete the Informed Consent Form, and a brief 
Pre-screening Survey. The 6-question pre-screening survey will determine the woman's 
eligibility to participate in the study. Upon meeting eligibility requirements, those participants 
who identified themselves as experiencing psychiatric comorbidities (depression, anxiety, 
obsessive compulsive disorder, attention deficit disorder, etc.) will make up the case group, 
those who do not identify themselves as suffering from psychiatric comorbidities will make up 
the comparison group.  
 The participants will then be directed to the study surveys, including: a Socio-
Demographic Questionnaire, the Premenstrual Symptoms Screening Tool (PSST), the 
Perceived Stress Scale (PSS), the Quality of Life Scale (QOLS), the Healthy Lifestyle 
Questionnaire (HLQ) and the Wellness Self-Perceptions Scale (WSPS). Each questionnaire 
and survey consists of approximately 15 questions and will require approximately 10 minutes 
to complete. A study participant should anticipate a total time allotment of 45-60 minutes to 
complete the surveys included in the study. Study participants will have one (1) week to submit 
their surveys and responses.   
Please see attached copies of EACH SURVEY and QUESTIONNAIRE 
11)    Data and Specimen Banking 
 All data collected throughout the study will be maintained in the HIPPA-compliant, 
Qualtrics secure database. Access to the Qualtrics' database will be limited to this doctoral 
candidate and her dissertation committee chair.  Data will be stored on the server for 5 (five) 
years.  
 
12)    Data Management 
 An a priori power analysis was conducted to determine the minimum necessary sample 
size in order to obtain a recommended statistical power of .80 (Cohen, J., 1992). Estimating a 
medium effect size for an independent groups t test, a sample size of 51 participants per group 
is expected to yield the desired statistical power.  Estimating a medium to large effect size 
yielded a recommendation for 30 participants per group. Therefore, this study will attempt to 
obtain at least 51 participants per group in order to improve the chances of detecting 
    
 
    
   
 
 
119
differences between women with PME who have psychiatric comorbidities and women who 
have PME but do not have psychiatric comorbidities on the study variables of interest.  
 Prior to data analysis, data will be entered into the database. Data will then be 
cleaned, coded, and assessed for shape of distribution and normative outliers. Data will first 
be analyzed descriptively to give readers a thorough description of the sample both in terms of 
demographics and how the participants scored on the measures used in the study. Missing 
data will be analyzed using multiple imputation; whereby, all available data from the subject 
will be used for analyses.   
 Analysis will include descriptive and inferential statistics to test the hypotheses.  A 
variety of statistical tests will be used to analyze and describe the data and draw associations 
between the case and comparison groups of women with PMDD. A bivariate correlation will 
also be run to determine any significant correlations among the study variables.   
Descriptive statistics. Data pertaining to frequencies, percentages, standard deviation and 
mean percentages will comprise the descriptive statistics. The socio-demographic data will be 
summarized and compiled into tables and charts to describe the various characteristics of the 
case group and the comparison group of women participating in the study.  
Inferential Statistics. Inferential statistics will be utilized to test the study hypotheses. One 
statistical test that will be used to address the hypotheses is the independent groups t test.  
This test can compare the means of two non-overlapping groups on continuous measures.  
Each of the hypotheses involves comparing women with PME who have psychiatric 
comorbidities to women with PMDD who do not have psychiatric comorbidities; thus, the 
independent groups t test is one of the analytic techniques, which will be utilized given the 
data to be analyzed. By comparing responses of the case group and the responses of the 
comparison group, inferences can be made as to the impact of PME on women with and 
without psychiatric comorbidities on physical and emotional symptoms, severity of symptoms, 
perceived life stress, quality of life, healthy lifestyle, and self-perceptions of wellness.  An 
unpaired t test will be utilized to compare the study outcome variables:  perceived life stress, 
quality of life and healthy lifestyle and wellness self-perceptions between women experiencing 
PME of symptoms with or without co-morbid psychiatric disorders.  
Statistical Tests. Hierarchical Multiple Regression Analysis will be used to measure the effect 
of psychiatric co-morbidities on symptom severity, the levels of perceived life stress, the 
quality of life, healthy lifestyle levels and levels of wellness self-perception among women with 
PME.  Three covariates will be entered in the first step (relational stress, occupational stress 
and lifestyle management), followed by psychiatric co-morbidity in the second step (will be 
reported as a yes/no dichotomous variable). The level of significance will be set at alpha = 
0.05 
 
13)    Provisions to Monitor the Data to Ensure the Safety of Subjects 
• NOT APPLICABLE  
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14)    Withdrawal of Subjects 
 Subjects will be informed that their participation in this research is strictly voluntary 
and that they may withdraw their consent to participate at any time.  There are no negative 
ramifications for the woman who decides to withdrawal her consent to participate in the study.   
 
15)    Risks to Subjects 
 The potential risks to the women who consent to participate in this study are minimal.  
This study does not involve treatment or interventions, but rather the gathering of information 
provided by the participant’s responses to the various rating scales.  The most prominent risks 
for the research participant relate to the time involved in completing the various 
questionnaires and survey forms.  These risks would be considered more ‘risks of 
convenience’ or ‘nuisance risks,’ as opposed to risks of discomfort or side effects.  Additional 
risks may include feelings of discomfort related to the content of some of the questions, as they 
are of a unique and personal nature.  
  
16)    Potential Benefits to Subjects 
• NOT APPLICABLE 
 
17) Vulnerable Populations 
• NOT APPLICABLE 
 
18) Multi-Site Research 
• NOT APPLICABLE 
19) Community-Based Participatory Research 
• NOT APPLICABLE 
 
20) Sharing of Results with Subjects 
 As this study does not involve medical procedures, tests or drugs, there are no direct 
results to share with the study participants.  As nurses, however, they may be interested in the 
published results of the study, which may appear in the nursing or other medical or 
psychosocial literature and an announcement of such publication will be made on the same 
nursing association membership databases used to recruit study participants. 
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21) Setting 
 Women with PME with and without co-morbid psychiatric disorders will be recruited 
from various nursing organization membership lists to complete various surveys and rating 
scales, which will be available, online. Registered nurses represent a cross-section of the 
female population, of all ages and all demographics; there are almost 2.7 million nurses 
employed in the United States and over 90 percent are women (Bureau of Labor Statistics, 
2013).  The membership lists of the following nursing organizations will be utilized to recruit 
study participants for both the case and control groups: 
• Division of Consumer Affairs, New Jersey State Board of Nursing (NJBON) 
• New Jersey State Nurses Association (NJSNA) 
• American Psychiatric Nurses Association (APNA) 
• Association of Women's Health, Obstetric and Neonatal Nurses (AWHONN) 
• University of Pennsylvania-School of Nursing 
• Drexel University-College of Nursing 
• Among other Nursing Organizations 
 As the study investigator maintains licensure as a Registered Nurse and Certification 
as a Family Psychiatric Mental Health Advanced Practice Nurse in the State of New Jersey, 
the databases of the NJBON and NJSNA were chosen.  As this study hopes to inform nurses 
across specialties, particularly the specialties of psychiatric and women's health nursing, 
APNA and AWHONN's memberships were chosen as additional recruitment sites. The 
American Academy of Nurses, the University of Pennsylvania-School of Nursing and Drexel 
University-College of Nursing were also chosen based on the doctoral candidate's 
associations and affiliations. 
 
22) Resources Available 
 Women with Premenstrual Symptom Exacerbation with and without co-morbid 
psychiatric disorders will be recruited from various nursing organization membership lists to 
complete various surveys and rating scales, which will be available, online. Registered nurses 
represent a cross-section of the female population, of all ages and all demographics; there are 
almost 2.7 million nurses employed in the United States and over 90 percent are women 
(Bureau of Labor Statistics, 2013).  This population justifies the feasibility of recruiting a 
minimum of 100 participants within a 3 month time period.   
 Laura Leahy, co-investigator and doctoral candidate, will devote a minimum of 16 
hours per week will be devoted to conducting and completing the research involved in this 
study.  Ms Leahy has previously acted as sub-investigator and study coordinator on various 
Phase 2, Phase 3b and Phase 4 pharmaceutical research studies.  Dr Barbara Posmontier, 
primary investigator and associate professor, will supervise Ms. Leahy's research efforts as 
her dissertation chair. Dr Posmontier has vast experience as a funded and published 
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researcher, including NIMH funding for an ongoing R-21 study of a "multidisciplinary Model 
of Nurse Midwife Administered Psychotherapy for Postpartum Depression." 
 As the research is being conducted over the Internet, there is no formal facility in 
which this study is being conducted.  This may, however, limit participants to those who have 
access to a computer and the Internet. 
 This study is being self-funded by Laura Leahy, as the dissertation research required 
to complete her Doctor of Nursing Practice (DrNP) degree at Drexel University. 
 
23) Prior Approvals 
• NOT APPLICABLE 
 
24) Recruitment Methods 
 Study participants will be recruited from each database by sending a "blast" email to 
the membership announcing the study and/or by posting an announcement of the study on the 
membership discussion board via the organization's website. 
  The first 100 women who consent, complete and submit the study questionnaires in 
their entirety will receive a $10 (ten dollar) e-gift card to either Starbucks™ or Amazon™ to 
acknowledge their participation in the study.  The e-gift cards will be distributed within 
approximately 6 week of the completion of data collection. 
 The initial recruitment will begin in June 2015, upon approval by Drexel University's 
Institutional Review Board.   
Please Refer to Attached Advertisement and Announcement Flyers 
 
25) Local Number of Subjects 
 All study participants will be recruited via the Internet; thus, they may be from 
across the United States and/or across the world as well as locally.  There is no 
specific number or limitation to the number of subjects from any given region or local. 
 
26) Confidentiality 
 In order to protect participants against the risk of a breach in confidentiality, a unique 
identifier will identify all participants. No personally identifying information will be collected 
on study participants. 
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27) Provisions to Protect the Privacy Interests of Subjects 
Every effort will be made to ensure participant confidentiality throughout the study 
and upon study completion. In order to protect participants against the risk of a breach in 
confidentiality, a unique identifier will identify all participants. No personally identifying 
information will be collected on study participants. All data collected throughout the study 
will be maintained in the HIPPA-compliant, Qualtrics secure database.  No Internet provider 
(IP) addresses will be collected or stored at anytime during the participant's engagement in 
the study, unless the participant voluntarily offers her email address to receive an e-gift 
card.as one of the first 100 participants to complete and submit the questionnaires.. Access to 
the Qualtrics' database will be limited to this doctoral candidate and her dissertation 
committee chair. 
 
29) Compensation for Research-Related Injury 
• NOT APPLICABLE 
 
30) Economic Burden to Subjects 
• NOT APPLICABLE 
 
31) Consent Process 
 The purpose, risks and benefits of participation will be explained in writing to all 
potential study participants.  Those women who agree to participate in the study will 
electronically sign a HIPAA-compliant consent form approved by the Drexel University 
Institutional Review Board. Subjects will be informed that their participation is strictly 
voluntary and that they may withdraw their consent to participate at any time.  There are no 
negative ramifications for the woman who decides to withdrawal her consent to participate in 
the study.  All participants will be provided with the email and phone contact information of 
the study investigators as well as the Drexel IRB. 
 The HIPAA Waiver of Authorization is being requested: 
The description of the protected health information (PHI)  has been included in the protocol 
summary and the PHI is necessary for the research to be able to help with the conclusion of 
the research. The use of the protected health information involves no more than minimal risk 
to the subjects, and the plan to protect the subjects identifiers from improper use and 
disclosure is that the data will only be available to only persons involved in the study.  The 
data will be stored in a private computer that is secure, encrypted and password protected, in 
a private office. The  subjects completing the questionnaires will be anonymous. If the subject 
chooses to receive the compensation being offered the study personnel will record the 
identifiers and they will be destroyed. The protected health information will not be reused or 
disclosed to any other persons except to those who are involved in the study.  The research 
could not practicably be conducted without the waiver, because the research could not be 
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conducted without the access to and use of the protect health information in order to help with 
our conclusion of the research. 
 
Non-English Speaking Subjects          NOT APPLICABLE 
Waiver or Alteration of the Consent         NOT APPLICABLE 
Subjects who are not yet adults (infants, children, teenagers)        NOT APPLICABLE 
Cognitively Impaired Adults      NOT APPLICABLE 
Adults Unable to Consent      NOT APPLICABLE 
 
32) Process to Document Consent in Writing 
 Consent to participate in the study will be obtained electronically. 
Please Refer to Attached Consent Form, Leahy Qualtrics Consent Form & Electronic 
Consent Script Documents 
 
33) Drugs or Devices 
NOT APPLICABLE 
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Appendix 3 
Drexel University IRB Proposal Application 
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FORM: Contact Information (Research Personnel) 
NUMBER DATE PAGE 
HRP-201 01/10/2014 1 of 2 
 
Version:  1/10/2014 
Please provide your contact information below for our database 
 New  Updated 
First Name Barbara 
Last Name Posmontier 
Job Title Associate Professor 
Department CNHP 
Company Drexel University 
Business Phone 215-762-4164 
 Cell Phone 215-495-3050 
Drexel Affiliated Email Address  Bp98@drexel.edu 
Alternate Email Address Bobbiepos@gmail.com 
Mail Stop 1030 
Mailing Address 
32 N. Lincoln Ave.  
Newtown, PA 18940 
Role in Research PI 
Involved in Consent  Yes     No     
 
  
All personnel are required to complete a Financial Conflict of Interest Disclosure Form 1. 
 
Form 1 (Requirement for all submissions)     Yes   
 
Form 1 web link: 
http://www.research.drexel.edu/administration/Forms_Facts/docs/FCOI_Disclosure_Form_1.pdf  
 
 
 
 
Any personnel acknowledging a conflict of interest in Form 1, must also complete the Financial Conflict of 
Interest Disclosure Form 2. 
 
Form 2 - Conflict of Interest Form Included:     Yes     No    
 
Form 2 web link: 
http://www.research.drexel.edu/administration/Forms_Facts/docs/FCOI_Disclosure_Form_2.pdf  
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FORM: Contact Information (Research Personnel) 
NUMBER DATE PAGE 
HRP-201 01/10/2014 2 of 2 
 
Version:  1/10/2014 
 
Name of Certification: 
Date of Certification: 
 CITI Group Specific Certification: Group 1   2   3   
(recertification every 3 years) 
01/07/2012 
    Responsible Conduct of 
Research (applicable to NSF grants) 
Date: 
01/21/2013 
 Health Information Privacy 
Security (HIPS) training  
*Recertification required every 3 years 
Date: 
10/08/2014 
 GCP (Good Clinical Practice) 
*Recertification required every 3 years 
Date: 
10/08/2014 
 Surrogate Consent (Required 
when using LARs to consent) 
Date: 
                                   
 HIPAA and Medical Research 
(Drexel Core) 
Date: 
08/15/2008 
   HIPAA e-Security   
(Drexel Core) 
Date: 
08/15/2008 
 Biological Shipment Training (annual recertification) 
Date: 
                                                                         
 Laboratory Safety Training  
(annual recertification) 
Date: 
                             
 Bloodborne pathogen    
training (annual recertification) 
Date: 
                                            
 
 
 
 
 
Signature Acknowledgement 
By signing below you are verifying that you will conduct this Human Research in accordance with requirements in the 
INVESTIGATOR MANUAL (HRP-103). 
Signature Date 
      
02/18/15 
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Page 1 of 1 
 
 
 
 Office of Research Administration 
 
Form (Revised 02/08/2013) 
FINANCIAL INTEREST DISCLOSURE FORM 1 
 
FULL NAME: _____________________________________________________________ 
 
PART A: REQUIRED TRAINING 
 
I certify that I have reviewed and understand the contents of the required training.  Link to Training 
 
PART B: SIGNIFICANT FINANCIAL INTEREST 
 
1. Have/will youi receive(d) income (e.g. gifts, favors, loans, services, salary, consulting fees), 
and/or have/will you possess(ed) an equity interest from/in a publicly traded entity deemed a 
Significant Financial Interest (SFI)
ii?  
 
        YES               NO      
2. Have/will you receive(d) income (e.g. gifts, favors, loans, services, salary, consulting fees) 
from a non-publicly traded entity deemed a SFI? 
 
        YES               NO      
3. Do/will you possess an equity interest in a non-publicly traded entity deemed a SFI? 
 
        YES               NO      
4. Do you receive income from any Intellectual property rights and interests (e.g. patents, 
licenses, royalties, and copyrights) deemed a SFI? 
 
        YES               NO      
5. Have/will you receive(d) reimbursed or sponsored travel deemed a SFI? 
 
        YES               NO      
 
If you have answered YES to any of the questions in Part B, please provide a list of all entities in the box below and 
complete, sign, and return an additional form, Financial Interest Disclosure Form 2, for each significant financial 
interest along with this form to the Office of Research Administration for further review. 
 
Entities/ Intellectual Property: 
 
 
I certify, to the best of my knowledge and belief, that the above questions have been answered correctly and that I will 
update and revise the answers as required. 
 
Signature _____________________________________________ Date _________________________ 
 
                                                           i You means you, your spouse, and/or dependent children. 
ii
 Significant Financial Interest (SFI) means a financial interest of a value exceeding a Defined Threshold* that is reasonably related to your Institutional 
Responsibilities ** and/or could reasonably affect or be affected by the outcome of the sponsored project and has been/will be possessed and/or received during 
a 12-month period prior to and/or after the disclosure.  The following EXCLUSIONS apply to the definition of a SFI: 
  Salary, royalties, or other remuneration paid by the University to University Personnel (UP) if UP are currently employed or otherwise appointed 
by the University, including intellectual property rights assigned to the University and agreements to share in royalties related to such rights; 
  Income from investment vehicles, such as mutual funds and retirement accounts, as long as UP do not directly control the investment decisions 
made in these vehicles; 
  Income from seminars, lectures, or teaching engagements sponsored by a Federal, state, or local government agency (Government Agency), an 
Institution of higher education as defined in 20 U.S.C. 1001(a) (Higher Education Institution), an academic teaching hospital, a medical center, or 
a research institute that is affiliated with a Higher Education Institution;  
  Income from service on advisory committees or review panels for a Government Agency, a Higher Education Institution, an academic teaching 
hospital, a medical center, or a research institute that is affiliated with a Higher Education Institution; 
  Travel reimbursed or sponsored by a Government Agency, a Higher Education Institution, an academic teaching hospital, a medical center, or a 
research institute that is affiliated with a Higher Education Institution; and 
  Grants and contracts administered through the University.  
 
*Defined Threshold means: 
  $5000 aggregate amount, on an entity-by-entity basis, for each of the following categories: 1) income from and equity in a publicly traded 
entity; 2) income from a non-publicly traded entity; and 3) reimbursed or sponsored travel.   
  $0 aggregate amount, on an entity-by-entity basis, for each of the following categories:  1) equity in a non-publicly traded entity; and 2) 
income from any intellectual property rights and interests. 
 
** Institutional Responsibilities means University Personnel’s professional responsibilities on behalf of the University, which may include for 
example: current or proposed activities such as research, research consultation, research-related student supervision, teaching, professional 
practice, institutional committee memberships, and service on panels such as Institutional Review Boards or Data and Safety Monitoring Boards. 
Barbara Posmontier
✔
✔
✔
✔
✔
✔
03/14/15
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Appendix 4 
Premenstrual Study Notice 
 
    
 
    
   
 
 
145
 
Appendix 5 
Premenstrual Study Recruiting Flyer 
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Appendix 6 
PremenstrualStudy.com Website Home Page 
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Appendix 7 
PremenstrualStudy.com Website Background Page 
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Appendix 8 
PremenstrualStudy.com Website Contact Page 
 
 
    
 
    
   
 
 
149
Appendix 9 
Premenstrual Study Informed Consent 
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Appendix 10 
Premenstrual Study Prescreening Questionnaire 
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Appendix 11 
Premenstrual Study Socio-Demographic Questionnaire 
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Appendix 12 
Premenstrual Symptoms Screening Tool 
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Appendix 13 
Perceived Stress Scale 
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Appendix 14 
Quality of Life Scale 
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Appendix 15 
Healthy Lifestyle Questionnaire 
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Appendix 16 
Wellness Self-Perception Rating Scale 
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residency and fellowship at Thomas Jefferson Medical College. Throughout his career, he has 
provided research on gender education, the provision of care to underserved women across the 
world and the prevention of sexual assault. Dr. Montgomery has held various positions within 
his professional organizations including: Past President, Philadelphia Obstetrical Society, 
Executive Board of ACOG and Chairman of ACOG District III.  He is widely published and 
frequently featured in videos related to obstetrics, gynecology and other women's health issues.   
    
 
    
   
 
 
168
 
 
